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Abstract 
 
Progress made in the palliation of those with terminal cancers has allowed most 
symptoms to be controlled if not completely alleviated. For many in this situation 
now, the most overwhelming and unpleasant ongoing problems are related to the 
accompanying cachexia. 
 
Cachexia -  (Greek,kakos-bad, hexis-condition) a wasting syndrome that causes 
weakness and a loss of weight, fat, and muscle(1) 
 
Cachexia has direct and tangible consequences such as reducing independence to a 
level where the patient requires institutional end of life care rather than being able to 
die in their own home or a place of their choosing. It also reduces survival 
independent of the primary disease histology, stage or the patient’s performance 
score(2) 
 
Upper gastrointestinal adenocarcinomas (i.e. oesophagus, gastric, pancreas, 
ampullary) often result in profound cachexia. Indeed unexplained weight loss is often 
the presenting symptom. There are often few other symptoms and consequently 
diagnosis is often made relatively late in the disease process, when the tumour has 
spread beyond the possibility of surgical cure. For a proportion of patients, 
chemotherapy and radiotherapy can offer substantial improvements but side effects 
often outweigh benefits. Many then either decide never to take these options or elect 
to stop taking them during the treatment course. A substantial proportion of people in 
this situation have no acceptable treatment options available to them. 
 
Previous attempts to medically manipulate this condition have been largely 
unsuccessful. Early small trials using thalidomide have pointed to a possible role in 
reducing loss of lean body mass but none have demonstrated a functional benefit or 
investigated underlying mechanisms.  
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In this trial we aimed to draw definite conclusions as to whether patients with terminal 
upper gastrointestinal adenocarcinomas would benefit from taking thalidomide. We 
also investigated the likely biological mechanisms underlying any effects. 
 
One of our major challenges was identifying a practical method for measuring lean 
body mass in a clinical setting. Measurement of lean body mass by Dual Energy X-
ray Absorptiometry (DEXA) is accurate but expensive, bulky, immobile and entails a 
small radiation dose. Our comparisons between methods of lean body mass 
measurement showed that anthropometry was a reasonable alternative to DEXA 
scanning (Gold Standard) but that bio-impedance produced an even more accurate 
result. We concluded that bioimpedance could be used as a valid alternate to DEXA 
in this population with the proviso that it as lean body mass falls it will tend to be 
underestimated by bioimpedance. 
 
We found thalidomide to be well tolerated but to offer no clinical benefit overall. In 
fact, at the three month visit those in the thalidomide group had a significant greater 
reduction in measured grip strength and the functional aspect of their quality of life as 
measured by questionnaire. Neither change was sustained at the six month visit. There 
was no measurable change in lean body mass between groups. The average survival 
was slightly higher in the placebo group but this difference was not significant (mean 
survival thalidomide group 83 days, placebo group 88 days).  
 
There was also a suggestion of some benefit of thalidomide therapy in those 
presenting with a more inflammatory disease as measured by plasma IL-6 and CRP. 
Sub-group analysis revealed that the thalidomide treatment group had a significantly 
longer survival over the placebo treated group if they presented with a higher than 
average IL-6 and a reduction in weight loss. Survival was significantly shorter with 
thalidomide treatment for those presenting with a lower than average IL-6. 
Thalidomide led to a significant suppression of plasma IL-6 levels over time. 
Unfortunately the survival advantage seen with thalidomide treatment in those with a 
more inflammatory state was not associated with any improvement in quality of life. 
The reduction in grip strength and functional quality of life was less marked in the 
thalidomide treated group but still present. 
 
 6 
It may be that thalidomide treatment leads to an overall reduction of muscular 
strength through its known side effect of somnolence leading to inactivity but that in 
treating the inflammatory component of cachexia it is able to improve survival. We 
suggest that future clinical trials of cachexia include measurement of peripheral 
cytokine measurements which seem to be strongly associated with outcomes. There 
may be a different anti-inflammatory medication or combination of treatments that 
could successfully treat the cachexia without the same side effect profile of 
thalidomide. Clinical benefits may be dictated by the degree of inflammation present 
at presentation and patients may need to be stratified for future therapies. 
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Chapter 1 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
“_the shoulders, clavicles, chest and thighs melt away. This illness is fatal_” 
—Hippocrates (460–370 BC) 
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 Clinical aspects of cachexia 
1.1.1 The syndrome 
Patients with a variety of chronic inflammatory conditions experience a progressive 
involuntary weight loss that can be profound. Termed cachexia, this syndrome is 
characteristic of patients with acquired immunodeficiency syndrome (AIDs); 
tuberculosis; rheumatoid arthritis; cardiac and respiratory failure and is strongly 
associated with advanced cancers, in particular those of upper gastrointestinal origin.  
 
Initially it was assumed that cancer cachexia may represent a host competition for 
nutrients by the tumour but doubt was shed on this theory by the recognition that 
many small tumours caused more intense cachexia than larger volume tumours(3). 
Loss of appetite is common in those with advanced cancers(4) but the weight loss of 
cachexia is not simply due to calorie deprivation. Attempts to prevent cachexia solely 
by improving appetite(5;6) or increasing calorie intake(7;8) have invariably failed. It 
has now been firmly established that it is an active inflammatory process, governed at 
least partly by the action of cytokines and tumour factors (see mechanisms section 
below). 
 
Weight loss due to cachexia results in changes in body composition more similar to 
infection related weight loss than starvation(9). In starvation the major loss tends be 
from adipose tissue. Protein is relatively preserved and what is lost is divided equally 
between skeletal and visceral muscle(10). In cachexia weight is lost preferentially 
from the skeletal muscle and adipose compartments with relative sparing of visceral 
proteins(11-13). In fact, the liver often enlarges in cachexia due to production of acute 
phase proteins(14). 
 
Table 1 Characteristic body composition changes in starvation vs cancer cachexia 
 Starvation Cachexia 
Body fat ↓↓ ↓↓ 
Skeletal muscle ↓ ↓↓ 
Visceral muscle ↓ →/↑ 
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Cachexia has been known to physicians for centuries as a ‘signum mali ominis’ (a 
sign of ill omen).  
 
Of all malignancies it is most commonly seen in those with gastric or pancreatic 
cancer, with over 80% losing some weight and a third losing greater than 10% of their 
pre-morbid weight(2). Patients with pancreatic cancer have an average 14% weight 
loss at diagnosis and 24.5% when death is imminent (15). 
1.1.2 Morbidity 
Previous studies have suggested that 90% of terminally ill people would choose to die 
at home but are often deeply concerned about being a burden to caregivers(16). 
Muscle strength is proportional to muscle mass(17;18) and the weakness associated 
with cachexia is proportional to the muscle atrophy experienced. In gastrointestinal 
cancer patients, weight loss of 2.5kg over a 6 to 8 week period is enough to cause a 
significant deterioration in performance status(19) and of multiple clinical 
measurements McMillan and colleagues regressed against the Karnofsky performance 
status in advanced gastrointestinal cancer patients, only lean body mass was an 
independent predictor of performance score in both sexes(20). This muscular atrophy 
and the fatigue caused by cachexia lead to difficulty carrying out normal activities, 
often reducing independence and necessitating institutional end of life care. The 
associated loss of appetite can also be debilitating. People enjoy eating and the loss of 
the desire to eat can itself adversely affect quality of life(21). It can also be extremely 
distressing for the patient and those around them to witness profound weight loss, an 
all too obvious sign of deterioration. 
1.1.3 Mortality 
Those with cachexia are significantly less likely to have a good response to 
chemotherapy and more likely to suffer toxic side effects(2). The cachexia itself is 
also a major cause of mortality, contributing to death in up to one in five cases(22-
24).The quantity of weight lost, and the rapidity with which it is lost, correlates 
inversely to survival, with death commonly occurring when the individual’s weight 
has dropped to 70% of previous levels(25). Patients with greater than 15% weight loss 
have significant impairment of respiratory muscle function, which probably 
contributes to the decreased survival time in those with the syndrome(2). 
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 Reduced energy intake 
Weight losing cancer patients have a calorie intake around 300kcal per day lower than 
weight-stable cancer patients(26). It is not uncommon for upper gastrointestinal 
cancer patients to have physical difficulty ingesting adequate calories: chemotherapy 
and radiotherapy induce nausea, vomiting and mucositis; tumour bulk and ascites can 
cause physical obstruction; and tumour invasion or intestinal resection can result in 
early satiety, shortened transit time, dumping syndromes, bacterial overgrowth and 
malabsorption. 
 
In addition, anorexia is present in up to 40% of cancer patients at presentation(27) and 
64% when terminally ill(28), with the resulting reduction in oral intake contributing to 
the energy deficit observed in cancer cachexia(29). In healthy humans weight loss is a 
potent stimulus for increased food intake and is governed by a network of feedback 
mechanisms. The absence of this response in cancer cachexia patients implies a 
dysregulation of the normal processes. The hypothalamus is the co-ordinating centre 
for energy balance. Here peripheral signals converge, bringing information 
concerning energy availability and requirements. This information is processed by 
neuropeptide pathways which stimulate or inhibit second-order neurons that convey 
the information to the periphery and govern eating behaviour.  
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1.2.1 Key mediators of eating behaviour 
 
Figure 1 Summary of the key factors in the regulation of the desire to eat in health 
1.2.1.1 Orexigenic factors  
1.2.1.1.1 Neuropeptide Y 
In health neuropeptide Y (NPY) is a powerful prophagic signal, repeated intra-
hypothalamic injections causing a six-fold increase in body weight gain in healthy 
rats(30). It is synthesized in tandem with agouti-related peptide (AgRP, see 1.2.1.1.2) 
by specific hypothalamic neurons. These AgRP / NPY neurons are stimulated by 
glucocorticoids and ghrelin but inhibited by leptin and insulin(31). NPY is up-
regulated at times of increased energy demand such as starvation, lactation or 
exercise(32). Anorectic tumour-bearing rats have decreased NPY immunostaining in 
their hypothalamic nuclei(33) and lack the normal mechanisms regulating NPY 
levels. If otherwise healthy rats have their food restricted in order that their body 
weight matches that of tumour bearing rats, then hypothalamic levels of NPY are 
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increased, stimulating appetite to recover the lost weight but in tumour bearing rats 
levels remain low(34). 
 
Tumour bearing rats also lack the normal responses to hypothalamic NPY. 
Hypothalamic receptors(35) and downstream messengers of NPY(36) are abnormal in 
these animals and the increased food intake resulting from intra-hypothalamic NPY 
injections in healthy rats is actually reversed. This effect occurs prior to the onset of 
anorexia but becomes more pronounced in parallel with the progression of the 
anorexia(37). A human study found significantly lower levels of circulating NYP in 
cancer patients than in controls but levels did not correlate with the degree of 
anorexia(38). 
1.2.1.1.2 Agouti-related peptide 
AgRP is also a potent appetite stimulator. It is a competitive antagonist to alpha-
melanocyte stimulating hormone (α-MSH) at melanocortin receptors MC3-R and 
MC4-R, thereby preventing their usual appetite suppressing effects (see 
1.2.1.2)(39;40). Central injection of AgRP in murine models leads to substantial 
increases in food intake(41). 
1.2.1.1.3 Ghrelin 
Ghrelin is released by gastric cells when the stomach is empty, approximately 
doubling before each meal and returning to baseline after eating(42). Baseline serum 
levels are inversely proportional to body mass index(43). It stimulates receptors on 
centrally located orexigenic cells(44) causing release of NPY(45) and AgRP via nitric 
oxide(46). Human studies have confirmed that peripherally administered ghrelin 
results in increased food intake(47). It has multiple physiological effects relevant to 
the cachexia syndrome including promotion of gastric emptying, potentially reducing 
nausea(48); inhibition of pro-inflammatory and stimulation of anti-inflammatory 
cytokines(49-52) and stimulating endogenous growth hormone and IGF-1, thereby 
increasing anabolism(53-55). In rats with burn injury it attenuates the usual rise in 
muscular TNF-α and IL-6 and inhibits skeletal muscular breakdown(56).  
 
Higher baseline levels of activated ghrelin are found in patients with cancer cachexia 
than either non-cancer controls or non-cachexic cancer patients(57). This is 
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appropriate for a weight losing state but does not seem to produce the desired 
peripheral effects, implying that cachexia is a state of ghrelin resistance. 
1.2.1.2 Anorexigenic factors 
1.2.1.2.1 Alpha-melanocyte stimulating hormone (α-MSH) 
Alpha-MSH stimulates melanocortin receptors MC3-R and MC4-R in the 
hypothalamus resulting in appetite suppression. Blockade of its precursor, pro-
opiomelanocortin (POCM), restores food intake in rat model cachexia but does not 
increase the intake of controls(58). 
1.2.1.2.2 Leptin 
Leptin is a hormone released from adipocytes(59), levels correlate with body mass 
index both in cancer cachexia and healthy subjects(60;61). It reduces NPY in the 
hypothalamus and binds competitively to the NPY receptor (Y-5)(62) producing a 
reduction in food intake(63). Inhibition of leptin or its signalling pathway leads to 
excessive eating and dramatic obesity in both mouse and humans(64-66). Generally a 
difference has not been demonstrated in circulating leptin levels between those with 
cancer cachexia and healthy subjects other than that expected due to the lower body 
fat of the cancer patients(61;67;68). The levels of circulating leptin transported across 
the blood brain barrier is known to vary in different health states (69) which could 
explain why combined results from human and animal studies have not been able to 
elicit clarity in the role played by leptin in cancer-related anorexia(70-72). 
1.2.1.2.3 Corticotrophin Releasing Factor 
CRF produces a multitude of critical physiological effects, mainly those of the stress 
response, including appetite inhibition(73). 
1.2.1.2.4 Serotonin 
Serotonin has been implicated in the process of cancer cachexia for decades(74). 
Hypothalamic serotonin induces production of corticotrophin-releasing factor (CRF) 
(75) and stimulates POMC neurons in the arcuate nucleus(76) so reducing appetite. 
Hypothalamic levels of serotonin are higher in tumour-bearing anorexic rats than in 
controls and food intake in these animals can be restored by hypothalamic injection of 
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a serotonin antagonist(77). Results from human studies are similar: levels of 
tryptophan (serotonin’s precursor and a valid substitute marker(78)) are higher in both 
plasma and CSF in anorectic cancer patients than either healthy controls or those with 
cancer but no anorexia(79). Upon successful removal of the tumour, both rats and 
human with cancer cachexia normalise their central and peripheral 
serotonin/tryptophan levels and food intake is re-established(77;80). Fenfluramine is a 
serotonin agonist and was widely used as an anti-obesity medication between 1973 
and 1997 when withdrawn due to links with cardiac abnormalities. 
 Increased energy expenditure 
In simple calorie deprivation resting energy expenditure (REE) declines in an attempt 
to preserve energy(81), both in the total REE and in the per unit REE (which takes 
account of the weight already lost)(82). Patients with pancreatic cancers have 
consistently been found to have an increased REE (total and per unit) (83) which is 
significantly higher in those presenting with an elevated C-reactive protein level(83). 
Results in those with oesophageal and gastric cancers have generally shown an 
increased REE(84) but have been a little less consistent(85), perhaps complicated by a 
partial calorie deprivation in those unable to eat adequately for mechanical reasons. In 
one study, the REE was increased in the cancer group by 120kcal per day. The 
amount of weight lost was equivalent to a loss of 120,000kcal (3 years at 
120kcal/day). In practise the weight loss in cachexia tends to occur over a period of 
weeks or months and some patients have been shown to experience weight loss 
despite a normal energy intake and normal REE(85;86). There must therefore be other 
factors involved but it seems likely that increased REE significantly contributes. 
 
There is good evidence that the tumour itself is the ultimate cause of this increase in 
REE. If the tumour is successfully removed the hypermetabolic state is ameliorated 
but unsuccessful tumour resection aggravates the condition(82).  
 
The mechanisms accounting for the imbalance of the appetite control(1.2.1) also 
affect the REE. NPY increases parasympathetic activity whereas POMC increases 
sympathetic activity, increasing REE. The normal compensatory mechanism for an 
increase in REE would be to increase energy intake but patients with cachexia 
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struggle to ingest more calories due to the difficulties discussed above. Voluntary 
energy losses are instead minimised by reductions in activity(87), manifest clinically 
as fatigue, apathy and depression(83). It has been suggested that if energy losses 
through REE were less then physical activity could be resumed(87). 
1.3.1 Gluconeogenesis 
The brain requires energy in the form of glucose or ketones (fatty acids cannot cross 
the blood brain barrier). At times of starvation glucose is made available by 
gluconeogenesis, producing glucose from a variety of sources, including amino acids. 
Although essential this is a costly process, both in terms of energy consumption (each 
glucose molecule produced uses six high energy phosphate bonds(88)) and the 
breakdown of skeletal muscle required to provide the amino acid substrate. In health 
this sacrifice of skeletal muscle is limited by a switch from gluconeogenesis to ketone 
production from fat but this does not occur in cachexia.  
1.3.2 Cori cycle 
It has long been known that tumour cells use the anaerobic glycolysis pathway to 
produce energy in contrast to healthy cell which use the aerobic tricarboxylic acid 
cycle, a phenomenon known as the ‘the Warburg effect’(89). Conditions within solid 
tumours become oxygen deficient when they are more than just a few cells in size but 
in fact this changed metabolism in tumour cells occurs even when they are supplied 
with plentiful oxygen(90). Pyruvate kinase is key in glycolysis and the recent 
discovery of an alternative form of this enzyme present in cancer cells suggests a 
probable mechanism for the effect. It may provide an advantage for the rapid growth 
required(91). Aerobic metabolism is roughly 40 times more efficient than anaerobic 
so this switch is one factor in the increased REE. 
 
Glucose metabolism under these conditions leads to the production of large amounts 
of lactate which is then converted back to glucose by the liver and extra-hepatic 
tissues by gluconeogenesis in another energy inefficient process known as the Cori 
cycle(92). Activity of the Cori cycle increases in weight losing colorectal cancer 
patients(93) and contributes to energy wastage, it has been estimated up to 
300kcal/day(94) 
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Figure 2 Cori Cycle 
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Figure 3 Simplified representation of the Cori cycle demonstrating energy wastage 
 
1.3.3 Uncoupling proteins 
Uncoupling proteins are mitochondrial proteins that separate oxidative 
phosphorylation from ATP production, instead releasing energy as heat. Uncoupling 
proteins types 2 and 3 are expressed in skeletal muscle and their mRNA is increased 
during tumour growth(95).  
 Structural changes 
Cachexia is associated with a multitude of complex metabolic changes, many of 
which increase REE(96-100). Some of the key changes are summarised in the Figure 
4. 
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Figure 4 Metabolic alterations in cachexia 
 
Figure 5 The main physiological changes seen in cancer cachexia subdivided by those affecting 
different bodily compartments 
 
1.4.1 Loss of lean body mass 
Muscle strength is proportional to muscle mass(101). It seems reasonable to assume 
that the morbidity and mortality associated with cachexia are due primarily to loss of 
lean body mass rather than body fat. Wasting of respiratory muscles in particular 
increases the risk of pneumonias(102) and respiratory failure which is so often the 
terminal event in end stage cancer patients. The muscle wasting associated with 
cachexia results from both a reduced rate of protein anabolism(103-105) and an 
increased rate of catabolism(105;106). 
1.4.1.1 Reduced anabolism 
Synthesis of lean body mass in cachexia may be limited by a lack of substrates as the 
required amino acids are diverted into increased synthesis of acute phase proteins and 
gluconeogenesis(107). There is also a vicious cycle of weakness leading to inactivity, 
which itself leads to reduced synthesis of skeletal muscle(108). 
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MyoD is a nuclear transcription factor. Its binding to the myosin heavy-chain 
(MyHC) gene is vital for production of the MyHC(109) that constitutes about 40% of 
the myofibrillar protein content in normal muscle(110). It is vital to muscle 
regeneration after injury but is down-regulated in tumour bearing rats with weight 
loss(111).  
1.4.1.1.2 Myostatin 
Myostatin suppresses muscle growth by inhibiting myoblast proliferation(112-115). 
Murine models have demonstrated that systemic overexpression leads to cachexia-like 
muscular atrophy(116) whereas gene deletion or administration of anti-myostatin 
antibodies result in skeletal muscular hypertrophy and increased strength(117;118) It 
may have a role in cancer cachexia but this is so far unproven, possibly in part due to 
the technical difficulties of human myostatin assays(119).  
1.4.1.1.2.1 Eukaryotic initiation factor 2 and Angiotensin II 
Eukaryotic initiation factor 2 inhibits the initiation of protein translation(120), 
angiotensin II acts in a similar way(121) and is capable of inducing a 40-50% 
depression in protein synthesis in murine myotubes(121) in addition to stimulating 
muscle protein degradation. Angiotensin II also increases protein breakdown(108) 
1.4.1.1.2.2 Insulin like growth factor (IGF) 
IGFs are proteins structurally similar to insulin which have a wide range of effects 
including inducing protein synthesis and preventing activation muscle breakdown 
pathways, particularly that stimulated by angiotensin II(122;122;123;123-125).  
1.4.1.2 Increased catabolism 
1.4.1.2.1 Proteolytic pathways 
Increased catabolism probably has a greater role than reduced anabolism in the 
muscle wasting of cancer cachexia(126). There are three major pathway of protein 
catabolism(126). Components of the first, the lysosomal system, are elevated in 
skeletal muscle biopsies from patients with lung cancer and minimal weight loss, 
probably playing a role in early protein breakdown. This pathway does not seem to be 
involved once the cachexia becomes established(127). 
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Subsequently muscle catabolism is processed by the other two proteolytic pathways. 
The calcium-dependent proteolytic pathway(128) destroys structural components of 
myofibrillar proteins, disassembling them into soluble actin and myosin components. 
A role for this pathway in cachexia is suggested by a demonstrable increase in soluble 
muscle filaments in skeletal muscle of rats with muscle atrophy induced by fasting, 
glucocorticoids or sepsis(129). Also, proteases involved in this pathway have been 
shown to be over-expressed in the atrophic skeletal muscles of diabetic rats and the 
appropriate protease inhibitors will attenuate the excessive muscle proteolysis(130). 
Despite this reasonable evidence for a role of this pathway in animal model, its 
contribution remains unclear in human cachexia.  
1.4.1.2.2 The ubiquitin-proteasome pathway 
Once solubilised by the calcium dependent pathway, actin and myosin are destroyed 
by the ubiquitin-proteasome pathway (UPP)(131), which accounts for up to 85% of 
protein degradation(126;132;133) in health. In addition to the destruction of these 
structural proteins, the UPP performs a vital function in removing short lived or 
abnormal proteins (e.g. damaged or degraded proteins produced by errors in gene 
transcription, mRNA translation or oxidative stressors(134;135)), thereby controlling 
cell cycles, signal transmission, immune response, tumour progression and 
apoptosis(126;136).  
 
A key component of the UPP is a cylindrical protein-degrading complex named the 
proteasome (the 26S complex), present in cell nuclei and cytoplasm. Prior to entry to 
the proteasome, target proteins are marked for destruction by the ATP-dependent 
attachment of chains of a small regulatory protein named ubiquitin. This allows the 
proximal end of the proteasome (the 19s complex) to recognise the target protein, 
remove and recycle the ubiquitin, and move the substrate through to the 
chymotrypsin, trypsin and caspase containing proteasome core (20S complex). These 
enzymes hydrolyse the protein into oligopeptides (6-8 amino-acids) which are then 
consumed in other processes. 
 
There is good evidence for this pathway being hyper-stimulated and causing increased 
destruction of muscular proteins in both animal and human studies of cachexia. 
Tumour-bearing animal models have demonstrated increased expression of elements 
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of the UPP (including ubiquitinated proteins) in skeletal muscle associated with an 
increase in muscle protein destruction compared with controls(137-140) and it has 
been shown that blockade of the UPP in incubated muscles from cachexic rats 
prevents their degradation(141;142). Muscle samples from people with 
gastrointestinal cancer cachexia show increased mRNA for specific proteasome 
subunits(143). Ubiquitin mRNA and proteasome activity also increases, positively 
correlating with disease stage and nutritional status (144;145).  
 
A number of steps in this pathway have potential to be regulated in order to control 
muscular destruction. Binding of the ubiquitin to the target protein requires at least 3 
sequential enzymic reactions termed E1, E2 and E3. E1 activates ubiquitin and passes 
it to the second enzyme, E2. E3 then binds between E2 and the substrate allowing 
ubiquitin to bind to the target protein. The initiation enzyme, E1, is a ubiquitous 
enzyme found throughout eukaryotic cells. Studies have shown that the baseline 
activity of this step is high, supplying ample active ubiquitin for the next stage(146) 
and that E1 supplementation does not increase ubiquitination(147). E1 is therefore 
unlikely to be a major control stage. Conversely, the conjugating E2 and E3 ligases 
exist in a number of different forms, each recognising different substrates. Higher 
regulation of these would allow fine control of the system(148) and in vitro 
supplementation of specific subclasses of E2 does up-regulate protein 
ubiquitination(147). Other subclasses of E2 have been shown to be induced at the 
mRNA level in rats with muscular atrophy induced by glucocorticoids(149) and in 
tumour-bearing rats(150). Specific E2 enzymes are suppressed by the anabolic 
insulin-like growth factor-1(149;151) and mRNA expression correlates with muscle 
proteolysis(151-153). E3 ligases are another likely target for regulation: specific E3 
ligases are up-regulated in muscles atrophying due to sepsis(154), insulin 
deficiency(126) and fasting(155) and mice lacking the gene for other E3 enzymes 
show less muscular wasting in response to denervation(156). E3 ligases which have 
attracted particular attention since their identification in 2001 include muscle ring 
finger 1 (MuRF1) and muscle atrophy F-box (MAFbx)(157). Knockout mice for 
MuRF1 and MAFbx genes are partially resistant to denervation induced muscle 
loss(150;156-158)., also both ligases are up-regulated both in animal models(159) and 
human conditions associated with muscular atrophy(160). MAFbx controls the 
degradation of MyoD (see 1.4.1.1.1), thereby controlling muscular anabolism as well 
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as catabolism(161). Other studies of E2 and E3 enzymes have been less convincing 
and the overall picture remains unclear(148) 
1.4.1.2.2.1 NFB  
NFB is a nuclear transcription factor expressed in almost all eukaryotic cells which 
regulates gene expression, so controlling a wide range of processes including immune 
function, apoptosis and oncogenesis(162;163). In relation to cachexia in particular it 
controls the UPP and production of MyoD(164). It exists as a trimer in cytoplasm, 
bound to DNA binding proteins and an inhibitory protein I-B(165). Inducible IB 
kinases (IKKs) phosphorylate IB so causing its destruction, leaving an active NFB 
dimer capable of translocation to the nucleus.  
 
It has been shown to increase in muscle atrophied from disuse and in vitro blockade 
inhibits protein loss in myotubules but the clearest evidence for its key role in 
cachexia was provided by an elegant animal model study by Cai(166). His group 
created genetically modified mice with hyper-activation of NFB. These mice exhibit 
profound skeletal muscle atrophy similar to that seen in cachexia and have raised 
levels of ubiquitin E3 ligase suggesting the increased NFB stimulates the UPP. 
Further evidence comes from the complete reversibility of atrophy in these mice with 
administration of a pharmacological proteasome inhibitor. They also demonstrated 
that by genetically adding a dominant inhibitory form of IB alpha, thereby 
preventing the activation of increased NFB, the muscle atrophy did not occur. Mice 
genetically modified with either inactive NFB or with deletion of an ubiquitin ligase 
are both resistant to tumour induced cachexia. More recent animal studies have 
suggested that blockade of NFB attenuates about half of cancer associated muscle 
atrophy(167). In health the action of NFB in muscle provides amino acids for 
essential energy sources for other tissues. In cachexia it appears to have become 
uncontrolled. 
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Figure 6 Summary of the ubiquitin-proteasome proteolytic pathway 
 
Figure 7 Represention of the breakdown of myosin heavy chains by the ubiquitin-proteosome 
pathway via ubiquination and then proteosomic breakdown 
 
Figure 8 Three main aspects of cachexia 
 
Figure 9 Cachexia is complex, involving loss of muscle mass, energy wastage and reduced 
appetite 
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 Biochemical orchestration of cachexia 
Three key findings conclusively demonstrate the presence of circulating tumour 
derived mediators driving cachexia: non-viable preparations of fat depleting mouse 
tumours transplanted into healthy mice induce fat depletion(168); in parabiotic rats, 
those paired with tumour bearing mates become cachexic in absence of 
metastases(169) and serum from tumour-bearing mice injected into healthy mice 
produces an immediate massive fat mobilisation that does not respond to 
feeding(170). It has now been firmly established that the cachexia is a para-neoplastic 
phenomenon caused by substances released either from the tumour or from other 
tissues as a response to the tumour, rather than from competition for resources from 
the tumour itself. 
 
Solid tumours are complex tissues, comprising of a variable mixture of primary 
tumour cells; tissue matrix cells such as fibroblasts and endothelial cells(171); and a 
variety of immune cells such as M2 macrophages, dentritic cells and T-regulatory 
leucocytes(172). Together, these cells produce a variety of tumour-derived mediators 
(proteins released from the tumour cells) and cytokines which promote the cellular 
proliferation, tissue remodelling and angiogenesis necessary for cancer development 
and progression(172;173) but also have far reaching consequences in the host. The 
exact mechanisms underlying these physiological changes are complex and remain 
incompletely understood.  
1.5.1 Pro-cachectic cytokines 
Cytokines are small, soluble communicating protein molecules present in every tissue. 
They are produced mainly from immune cells and regulate a multiple of biological 
responses. They form complex networks, with each cytokine influencing the 
production of others. There is substantial overlap in their effects and individual 
cytokines may have different actions in different environments(171). The tumour 
microenvironment is awash with cytokines produced both by the tumour cells and by 
the infiltrating cell populations(174). They are also released from the periphery, 
including the brain, as part of the host’s response to the tumour. Cytokines commonly 
implicated in the cachexic process include tumour necrosis factor alpha (TNF-
α)(175;176), interleukin 6 (IL-6)(177;178), interleukin 1 beta (IL-1β), and interferon 
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gamma (IFNγ)(179-181). Messenger ribonucleic acid (mRNA) encoding receptors for 
all of these cytokines can be found in skeletal muscle(182) and they are often raised in 
the serum of people with a variety of cancers, particularly when associated with 
cachexia(183). Chronic administration of these cytokines in animal models leads to 
anorexia, increased protein degradation, decreased protein synthesis and amino acid 
uptake, resulting in a clinical syndrome closely resembling cachexia. In some cases 
though, administration of more than one cytokine in tandem is necessary to produce 
the effects(184). 
 
Research into cytokine effects is complicated by the regulatory effects of one cytokine 
on another. For example, administration of IL-1 and TNF-α leads to in vivo 
production of IL-6. It is therefore a challenge to elucidate whether the effect of an 
individual cytokine is direct or indirectly mediated by the release of others. Animal 
models of cachexia allow more precise experimental manipulation but these models 
are artificial and each varies, with different cytokines and proteolytic pathways taking 
prominence and showing different responses to the same cytokine stimulants or 
suppressants(175;176;185-190). It is also probable that human cancer cachexia not 
only differs in its mechanisms from the animal models, but also that different people 
and different cancers produce different catabolic phenotypes, engaging individual 
cytokine cascades. 
1.5.1.1 Cytokines and anorexia 
The anorexia associated with cancer cachexia seems to be governed largely by 
cytokines(191). Inflammatory cytokines are known to have cerebral receptors, mainly 
centred in the hypothalamus(192). They can produce central effects by a variety of 
mechanisms: they can be produced within the brain(193-195); they can travel across 
the blood brain barrier (BBB) into the brain from the periphery(69;192); they can bind 
onto the peripheral side of the endothelial cells forming the BBB, stimulating them to 
release anorexic substances on the central side and they can disrupt the BBB, allowing 
increased passage of other substances including immune cells(69). All of these 
systems could be potential methods of regulation, for example a significant proportion 
of a peripherally administered dose of these cytokines will be transported into the 
brain across the BBB via selective, saturable systems (69;192) but the proportion 
transported will be altered in a variety of disease states(69). Studies of chronic 
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inflammation, including those in non-intestinal cancer cachexia, consistently find an 
inverse relationship between the leptin level and levels of pro-inflammatory 
cytokines(72;196;197). Il-6 in particular is similar structurally and functionally to 
leptin(198) and it has been postulated these cytokines could be reducing appetite by 
mimicking the anorexic effects of leptin (see 1.2.1.2.2) in the hypothalamus(192;199). 
In animal models they also increase hypothalamic serotonin activity and CRF 
levels(200), so stimulating the anorexigenic POMC pathway.  
1.5.1.2 Cytokines and the UPP 
The same cytokines have the ability to activate NFκB by causing destruction of the 
IκB inhibitor protein so stimulating muscular breakdown via the UPP. Often the 
activated NFKB will in turn stimulate production of further pro-inflammatory 
cytokines creating a positive feedback loop(166).  
1.5.2 Tumour necrosis factor alpha (TNF-α) 
 
 35 
Figure 10 Flowchart summarising known actions of TNF-alpha in cachexia 
 
Figure 11 TNF alpha is a direct mediator of many of the process involved in cachexia and affects 
local and peripheral levels of other cytokines which are mediators in turn. 
 
In 1975 Carswell et al discovered a serum factor capable of inducing haemorrhagic 
necrosis of tumours and named it Tumour Necrosis Factor alpha (TNF-α)(201). 
Beutler et.al. separately isolated ‘cachectin’ secreted by macrophages which induced a 
hypertriglyceridaemic state through suppression of lipoprotein lipase(202). It was 
subsequently shown that cachectin and TNF-α were in fact to be the same factor and 
that administration of this molecule to mice induced anorexia, weight loss and the 
depletion of whole-body protein. More recently there has been plentiful evidence 
implicating it as having a role in the syndrome of cancer cachexia but results have 
been varied and the detail is often conflicting. It is mainly produced by macrophages, 
T cells and natural killer (NK) cells in response to bacterial toxins, inflammatory 
products and other invasive stimuli but also, at lower concentrations, by tumour 
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cells(203). TNF-α binds to one of two receptors, either TNF receptor-1 (TNFR-1, p55 
receptor) or TNF receptor-2 (TNFR-2, p75 receptor) which are expressed on virtually 
all nucleated cells(204) and have distinct but overlapping functions. Binding to either 
of these receptors releases active NF-B by stimulating IKK(205;206). It also induces 
production of other inflammatory cytokines, including IL-1, IL-6 and IFN-γ from 
macrophages and NK cells(207). TNF-α can be pro- or anti-oncotic, varying 
according to the situation and the dose of the cytokine. Synthesis of low levels of 
TNF-α within the tumour itself enhances tumour growth through increasing 
angiogenesis via IL-8 release(208;209) and by facilitating invasion and migration of 
tumour cells(210;211). TNF-α deficient mice have been shown to be resistant to skin 
cancers(212). Conversely, higher TNF-α levels lead to tumour cell death and vascular 
collapse(213) and TNF-α deficient mice are unable to reject a synthetic fibrosarcoma 
until TNF-α is replaced(214). 
 
Administration of recombinant TNF-α has been shown to produce a syndrome closely 
resembling cachexia both clinically and physiologically in mice(215), 
rats(163;216;217), and humans(218). It has also been demonstrated in mice that 
transplantation of TNF-α secreting tumours produces a similar syndrome and that 
anti-TNF-α antibodies attenuate tumour induced cachexia(215;219;220). Artificially 
inhibiting TNF-α production also attenuates cachexia in a mouse cancer cachexia 
model (221). In human studies elevated serum TNF-α levels have been found in 
prostatic(215), lymphoma(222), oat cell cancer(222), ovarian cancer(222), 
breast(215), lung(223) pancreas(224). It has also been shown that the increase in 
TNF-α mRNA transcripts seen in pancreatic cancer patients normalises after resection 
of the tumour(225). In many studies, for example in pancreatic(224;226;226) and 
prostate cancer(215), TNF-α levels correlate with clinical outcomes such as lower 
body mass index, weight loss, lower haemoglobin, lower albumin, more advanced 
disease stage and shorter survival times. Results have not been entirely consistent and 
have not always correlated with degree of cachexia or tumour stage(227;228). This 
could be partly due to difficulty in measuring the protein because of its short half-life 
and at its lability in sub-optimal storage conditions(222;225). Levels may also be 
affected by a number of gene polymorphisms for TNF-α which affect constitutive and 
inducible level of TNF-α and susceptibility to, severity and mortality rates of a 
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number of infective (229-231), and immune diseases(232;233) and associated with 
prolonged ventilation after surgery(234), These polymorphisms were not found to 
correlate with serum levels of TNF-α or have any clinical relevance in pancreatic 
cancer patients(224). 
1.5.2.1 TNFR1 and TNFR2 
The TNF-α receptors are key in mediation of cachexia. Knockout mice lacking the 
TNFR1 gene do not develop the cachexia in response to tumour implantation seen in 
wild type mice(235). The active receptors are membrane bound but the extra-cellular 
domain is cleaved by TNF-α converting enzyme (TACE) into soluble, circulating 
receptor fragments (sTNFRs). These behave as natural TNF-α inhibitors, binding and 
sequestering it, so preventing it binding to their active, membrane bound 
equivalents(236). In mice with TNF- secreting tumours, infusion of sTNF receptors 
allow them to grow and reproduce normally(215). There are a variety of 
polymorphisms of these receptors. Different variants show different strength of action 
and circulating levels of the soluble receptors (236). They do seem to have clinical 
relevance with sTNFR levels and TNFR2 gene polymorphisms being associated with 
heart failure, obesity & insulin resistance(236). Presence of biologically active TNF-α 
is reflected by higher sTNFR levels but they are more stable over time and are used in 
many studies as a substitute marker for TNF-α(237). Similarly to TNF-α, sTNFR 
levels have been shown to be elevated in weight losing cancer patients(238) 
1.5.2.2 TNF-α in altered energy balance 
TNF-α administration leads to a reduction in food intake(191;191;239). The exact 
mechanism for this remains elusive but it can be replicated by intracerebroventricular 
infusion so presumably is centrally mediated(240). It has also been shown that TNF-α 
increases expression of genes encoding both for leptin(72) (resulting in anorexia, see 
1.2.1.2.2) and uncoupling proteins 2 and 3(95;241) (resulting in energy transfer into 
heat production rather than anabolism, see 1.3.3). TNF-α induced anorexia can be 
blocked by cyclooxygenase inhibitors (see 1.6.3.4), suggesting a prostaglandin based 
mechanism(242). 
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1.5.2.3 TNF-α in altered protein metabolism 
Skeletal muscle of weight losing patients shows increased expression of TNF-α and 
TNFRs(243;244), resulting in both reduced protein synthesis and increased protein 
breakdown. TNF-α inhibits synthesis of myosin heavy chains both in vitro and in 
vivo, it also blocks the anabolic effects of IGF-1(245) and growth hormone(246). In 
cardiac cachexia, IGF-1 mRNA levels negatively correlate with TNF-α levels in 
skeletal muscle(247). Also, in vitro, TNF-α acts synergistically with IFN-γ to inhibit 
activation of mRNA for MyHC(119;132) and in animal models TNF-α administration 
leads to decreased MyHC mRNA(248), mediated by a reduction of MyoD 
mRNA(249;249)(see 1.4.1.1.1). 
 
A role for TNF-α in increased protein breakdown is convincing and seems to be 
mediated mainly via the UPP(138) at a number of different stages in the pathway. 
TNF-α activates NF-B through degradation of IB(249-253) leading to a loss of 
myosin which can be blocked by over-expression of IB(250). TNF-α also increases 
ubiquitin gene expression and ubiquitin in skeletal muscle(254-257), TNF-α 
antibodies reduce ubiquitin gene expression in skeletal muscle(258-260) and prevent 
the associated increase in protein catabolism(139). Administration of TNF-α also 
leads to induction of specific E2 and E3 ligases both in vitro and in the resultant 
atrophying skeletal muscle in vivo(139;261;262). 
 
Again results from different studies have been inconsistent. Human studies are 
difficult to carry out and animal models are by their nature artificial. In some animal 
models anti-TNF-α antibodies are entirely ineffective in attenuating cachexia but 
other anti-cytokine antibodies (e.g. anti-IL6(263) or anti IFNγ(264)) work well.  
1.5.3 Interleukin 6 (IL-6) 
Il-6 is produced as part of the acute phase response in the liver and levels often 
mirrors C reactive protein (CRP)(265). It is also produced by most cell types at a local 
level in response a number of inflammatory and infective stimuli including TNF-
α(266;267). In mice, subcutaneous tumour implantation causes splenic IL-6 levels to 
increase a few days before the onset of cachexia(267) and monocytes from pancreatic 
cancer patients with cachexia (but not those from patients without cachexia) stimulate 
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production of unusually high levels of IL-6 from cancer cell lines in 
vitro(227;268;269). Reports are fairly consistent that Il-6 is elevated in cancer patients 
locally at the tumour site(270), in the serum(223;238;265;271;272) and in skeletal 
muscle(244), often in tandem with elevated TNF-α(268). Levels generally correlate 
with tumour stage, degree of cachexia, nutritional markers, increased resting energy 
expenditure and survival(238;265;268). 
 
In vitro, IL-6 causes destruction of myotubules(273) and artificially elevating 
circulating Il-6 levels in animal models to above physiological levels leads to atrophy 
of previously healthy muscle(274-279). Mice genetically engineered to have high 
levels of IL-6 show muscle atrophy which is reversible by IL-6 receptor 
antibody(280); rats treated with IL-6 undergo increased muscle breakdown(275) and 
microinfusion of IL-6 directly into a rat leg muscle leads to 9% reduction in protein 
with a 17% reduction in myofibrillar content compared to the contralateral muscle 
after a fortnight(278;279). Whether these effects occur with chronic low dose 
administration more akin to the levels seen in cancer cachexia is less certain. 
 
The cachexia produced in one of the major animal models, the murine Colon-26 
adenocarcinoma, is IL-6 dependent and is preventable by IL-6 receptor antagonists or 
anti-IL-6 monoclonal antibodies(187;187;190;263). If the tumour is resected then IL-
6 levels reduce and cachexia is reversed(177). Interestingly the clones of colon-26 
that do not produce cachexia also do not produce IL-6(281). In this model anti-TNF-α 
therapies have no beneficial effect(263). Anti-IL-6 antibodies are also protective 
against cachexia produced by inoculating mice with human prostatic and melanoma 
tumours(190). The APCmin/+ mouse model has a mutated adenomatous polyposis coli 
gene and develops dysplastic colonic polyps by 4 weeks of age. By 6 months these 
mice have a 45% reduction in gastrocnemius muscle mass compared with wild 
type(282). In this model a higher IL-6 serum level correlates with a higher degree of 
cachexia. The cachexia is prevented by genetic deletion of IL-6 but reinstated by 
systemic IL-6 replacement(283). In this model Il-6 mRNA is not elevated in muscle, 
suggesting a distant source of the cytokine(284). Similar to TNF-α there are 
polymorphisms of IL-6, some of which have been found to have clinical significance 
in a variety of situations(285-288), including general longevity(289) and susceptibility 
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to breast cancer(290). Early data are suggesting a relevance of some polymorphisms 
to susceptibility to the development of cancer cachexia(291). 
1.5.3.1 IL-6 in altered energy balance 
It is long established that IL-6 causes anorexia. Il-6 is closely related to leptin(267) 
and it has been postulated that it mimicks its hypothalamic effects(292). This may 
account for the lack of compensatory increased intake usually seen in response to 
weight loss but is unlikely to be the primary cause of the cachexia. Interestingly, IL-6 
knockout mice have increased susceptibility to intracellular infections, impaired 
wound healing and defective inflammatory responses but do not become obese in the 
way that leptin deficient animals do. Il-6 does not obviously account for the asthenia 
often associated with cachexia. Administration of supraphysiological doses of IL-6 to 
rats, adequate to cause muscle atrophy, have no effect on physical activity(276). In an 
animal model, IL-6 and TNF-α induced anorexia is prevented by cyclooxygenase 
inhibitors, suggesting that a prostaglandin such as PGE2 may be involved in the 
pathway (242). 
1.5.3.2 IL-6 in altered protein metabolism 
Administration of systemic IL-6 to healthy human volunteers results in a 50% 
reduction in muscle turnover acutely, mainly due to a reduction in protein 
synthesis(293). Effects of chronic administration are not known. Mechanisms of 
action of IL-6 in muscle atrophy are not as clearly defined as those for TNF-α. Any 
effect seems to be indirect or synergistic as incubation of muscle in vitro with pure 
IL-6 does not cause proteolysis (294). In a mouse model, levels of atrogin-1, an E3 
ligase, rise with both cachexia and with artificially increased IL-6(284), suggesting 
involvement of the UPP. 
1.5.4 Interleukin 1 beta (IL-1β) 
IL-1β is part of the IL-1 superfamily and is closely related to IL-1α with overlapping 
pro-inflammatory effects. Both cytokines produce their effects through the same IL-1 
receptor. Blocking this receptor in tumour bearing mice attenuates loss of body fat 
and lean tissue and reduces systemic IL-6 levels(219;295). IL-1β is necessary for 
murine tumour growth. Implantation of melanoma, prostate or mammary cancer cells 
into IL-1β knockout mice does not develop into either the local tumour or lung 
 41 
metastases seen in wild type mice. This is seems to be due to an absence of 
angiogenesis which is restored by addition of IL-1β and replicated by addition of an 
antagonist to the IL1 receptor in wild type mice(296). Evidence for IL-1β having a 
key role in angiogenesis is increasing(297;298). It has also been shown that certain 
IL-1 gene polymorphisms significantly affect survival in pancreatic cancer 
patients(299). 
1.5.4.1 IL-1 receptor antagonist 
IL-1RA is a naturally occurring antagonist to IL-1 which competitively binds to the 
IL-1 receptor(300). It behaves as an inhibitor to IL-1 mediated inflammation. Nine 
infants have been reported who were born with genetically defective IL-1ra. They all 
had widespread inflammatory consequences, including septic-like organ failure but 
with sterile cultures. IL-1ra is now commercially available as anakinra (Kineret®) and 
was effective and life-saving in these infants(301;302). Anakinra is now used 
therapeutically to control inflammation in rheumatoid arthritis patients. There are 
known polymorphisms of the IL-1ra which have been shown to affect survival times 
in human colorectal cancer(300) 
1.5.4.2 IL-1β in altered energy balance 
Similar to IL-6, IL-1β has long been established as a cause of anorexia(303;304). The 
effect seems to be mediated centrally(240), cerebral IL-1 levels in tumour bearing rats 
negatively correlate with food intake(239;305). Recombinant human IL-1α and IL-1β, 
and murine IL-1α administered systemically to rats causes anorexia(216;217) and 
hypothalamic IL-1ra injections causes an increase in food intake(306). The exact 
mechanism is unclear but anorexia in rats induced by IL-1β administration can be 
abolished by pre-treatment with either ibuprofen or fish oil, again suggesting a 
prostaglandin based mechanism(242). Intracerebral infusion of IL-1β leads to an 
increase in hypothalamic IL-1β and IL-1ra mRNA but also a reduction in 
hypothalamic NPY mRNA and increase in serotonin, both possible mechanisms of 
appetite suppression(307). Lastly there are complex interactions between IL-1 and 
leptin. Injection of leptin to rats both peripherally and centrally induces an increase in 
hypothalamic IL-1β and an anorexia which is preventable with co-administration of 
either IL-1ra or a cyclooxygenase inhibitor, suggesting leptin, IL-1β and 
prostaglandin are factors in the same pathway(308). Equally administration of IL-1 to 
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mice, hamsters and to healthy human volunteers causes an increase in serum leptin, 
although this response wears off over time(309) 
1.5.4.3 IL-1 in altered protein metabolism 
The bulk of evidence for IL-1β in cachexia relates to a role in anorexia rather than 
structural changes but there is evidence that it indirectly influences levels of other 
mediators such as IGF-1 which in turn affect muscle turnover(247). 
1.5.5 Interferon gamma (IFN-γ) 
IFN-γ is produced by activated T cells and natural killer cells. Nude mice inoculated 
with IFN-γ producing cells develop cachexia and IFN-γ antibodies reverse cachexia in 
murine and rat models(264;310). 
1.5.6 Vascular endothelial growth factor (VEGF) 
VEGF induces the angiogenesis vital for tumour growth(311-313). Several studies 
have shown that serum VEGF levels rise in a variety of cancers, correlate with the 
stage of disease and normalise after successful tumour resection(314-316). More 
recently it has become clear that VEGF has a larger role in cancer development than 
solely in controlling angiogenesis. Importantly, it dampens the response of immune 
cells in the tumour microenvironment, partly through recruitment of T regulatory 
cells, permissing tumour growth(317) and sustains the self-renewal of cancer 
stems(318). TNF-α stimulates VEGF production via NFκB(319). 
1.5.7 Proteolysis inducing factor (PIF) 
PIF is a glycoprotein produced by tumour cells which was first isolated relatively 
recently by Tisdale’s group from a cachexia inducing murine MAC 16 
adenocarcinoma model(320). Again this factor seems to be specific to certain animal 
models and is of no consequence in the widely used Yoshida ascites hepatoma 
model(321) but it does seem to be important in human studies. In patients with 
gastrointestinal cancers, PIF is produced specifically by those tumours associated with 
weight loss(322) and is detectable in the urine only at times of weight loss(323). Also 
the presence of PIF in urine of pancreatic cancer patients correlates with the amount 
of weight lost(324) and when the substance was isolated from human urine it is 
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capable of inducing cachexia in mice (an effect that can be prevented by prior 
administration of the mouse monoclonal antibody)(325). 
1.5.7.1 PIF in altered energy balance 
PIF does not have known direct effects on energy balance but it may produce indirect 
effects through induction of other cytokines, IL-6 in particular(326;327). 
1.5.7.2 PIF in altered protein metabolism 
Injection of PIF into healthy mice causes an increase in gastrocnemius ubiquitin 
mRNA and a variety of proteasome subunits in association with muscular 
atrophy(328) In vitro, PIF induces NF-B via breakdown of IB, increased activity of 
an E2 ligase and increased proteolytic activity of the proteasome(328-332). The 
increased NF-B also leads to increased TNF-α and IL-6 from Kupffer cells and 
monocytes(333). The proteolysis mediated by PIF in cachexia is specific to skeletal 
muscle, not affecting cardiac or renal muscle in the way that other cytokines such as 
TNF-α do(334;335). 
1.5.7.3 PIF controversy 
There are conflicting results in studies of every cytokine and tumour factor but the 
role of PIF in cachexia is questioned even more than others reviewed here, possibly 
due to its novelty. Despite the convincing evidence in the studies reviewed above 
others have found less positive results. It has been shown to be unrelated to weight 
loss, anorexia, survival or even the presence of cancer by several groups(336-341) 
although some of these negative studies assessed a non-active form of the 
substance(342). 
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Figure 12 Summary of cytokine interactions
 
 
Figure 13 summary of the interactions of the cytokine network leading to the syndrome of 
cachexia including those parts of the process targeted by therapeutic agents including 
thalidomide 
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 Potential therapies 
1.6.1 Increased calorie intake 
Various methods have been investigated  
1.6.1.1 High calorie diets 
1.6.1.1.1 Dietary counselling 
Attempts to prevent cachexia through dietary counselling have been invariably 
unsuccessful(8) 
1.6.1.1.2 Parenteral and enteral feeding 
Artificial nutrition by the enteral route leads to weight gain, decreased inpatient stays 
and improved mortality in malnourished older patients(343). Its role in cancer and 
cachexia is less clear. It can produce weight gain but this is mainly fat rather than 
useful lean body mass(344) and generally does not translate into benefits in morbidity 
or mortality(344-351) although one RCT in 300 patients with solid tumours and 
cachexia did suggest improved survival and exercise capacity if parenteral nutrition in 
combination with cyclooxygenase and erythropoietin was instigated when voluntary 
intake fell below 70% of recommended (30kcal/kg/day). Although forced calorie 
increase does not seem to be beneficial, it maybe that specific nutrients contained in 
parental nutrition therapy such as arginine, glutamine and fatty acids have benefit. 
Concerningly, other data suggest that these nutrients may prevent apoptosis and 
stimulate tumour growth(352) 
1.6.1.2 Orexigenic agents (appetite stimulants) 
1.6.1.2.1 Corticosteroids and progestagens 
Corticosteroids and progestagens (Medroxyprogesterone Acetate and Megesterol 
Acetate) are well known to produce increases in appetite and body fat (but not lean 
body mass) both in health and in cancer cachexia(353-356;356-360). Mechanisms 
remain incompletely understood but there is up-regulation of NPY and down-
regulation of serotonin and anti-inflammatory cytokines such as TNF and Il-1(361-
364). They can cause a short term feeling of well-being but are equally likely to cause 
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aggression or confusion. They do not produce any long term clinical 
benefits(357;365-369) and have troublesome medium to long-term consequences 
including insulin resistance(370) and muscle atrophy, probably via up-regulation of 
the UPP(371;372). 
1.6.1.2.2 Cannabinoids 
Dronabinol, a synthetic form of the active ingredient in marijuana, stimulates appetite 
in advanced HIV disease(373;374), working through cytokines or direct stimulation 
of endocannabinoid receptors(375-377). Unfortunately it does not reliably increase 
appetite in cancer patients(184), has no proven clinical benefit(370) (378;379;379) 
and has a number of negative effects such as loss of concentration and coordination, 
fluid retention and impotence(365). There is no additional benefit in using steroids 
and cannabinoids in combination(378). 
1.6.1.2.3 Serotonin antagonists 
Cyproheptadine may be beneficial in cachexia related to carcinoid(380) but has not 
proven helpful in other cancers(370;381). Ondansetron is helpful for nausea but does 
not lead to weight gain(382). 
1.6.2 Anabolic agents 
1.6.2.1.1 Androgens 
Androgens are a promising treatment with exciting recent trial results. They are not 
particularly effective as appetite stimulants(359) but they are able to increase net 
protein synthesis and increase lean body mass at the expense of body fat(383) 
 
Addition of nandrolone deconate to chemotherapy in non-small cell lung cancer led to 
attenuation of weight loss(384) in a prospective randomised trial. Oxandrolone in 
combination with dietary advice and exercise led to an average 4lb increase in lean 
body mass and increase in functional ability (average Eastern Cooperative Oncology 
Group performance score dropped from two to one) over 4 months in a 131 patient 
open label trial(385). In a prospective randomised phase 3 trial comparing 
oxandrolone to megesterone acetate on 155 patients with solid tumours and cachexia 
receiving chemotherapy, oxandrolone treatment was associated with increased LBM 
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and reduction in body fat whereas megesterone acetate was associated with increase 
in appetite, weight and body fat but not LBM. It was suggested that a combination of 
these agents could be beneficial(386). Similarly positive results have also been shown 
in muscle wasting in the otherwise healthy elderly(387), HIV disease(388) and 
chronic obstructive airways disease(389) but there are real concerns over unwanted 
peripheral effects. 
 
Enobosarm is a first in class non-steroidal selective androgen receptor modulator. It 
acts on androgen receptors in the skeletal muscle with a more limited effect on those 
in the liver, skin and prostate with the intention of limiting side effects. A recent 
phase 2 trial with randomised 159 patients with cancer cachexia (varied primaries) to 
enobosarm or placebo. Those in the enobosarm group showed a relative gain in LBM 
(by DEXA) and improved physical function with few side effects(390). 
1.6.2.1.2 Growth Hormone 
Growth hormone may increase skeletal muscle mass at the expense of tumour growth 
in animals(391) but increases mortality in critically ill human studies, possibly due to 
a blunting of the acute phase response through diversion of amino acids substrates to 
muscle synthesis(392). It may be that using ghrelin to cause the release of endogenous 
growth hormone is a safer alternative(see 1.6.2.1.3)(392;393) 
1.6.2.1.3 Ghrelin 
Both animal model studies(394) and human trials of ghrelin in cachexia have been 
positive(54;393;395). It increases food intake and grip strength in cardiac cachexia 
patients(396). In cancer cachexia patients offered a buffet lunch, administration of 
ghrelin led to a 31% increased intake and a 23% increase in the perceived 
pleasantness of the meal compared with administration of a placebo(54). Ghrelin 
requires parenteral administration and is expensive. There as yet unproven and 
conflicting links between ghrelin and mitosis(397-403). 
1.6.3 Anti-cytokine treatments 
The background information presented above presents a compelling rationale for the 
therapeutic use of anti-inflammatory cytokines (e.g. IL-4, IL-10, IL-12, IL-15) or 
neutralisation of pro-inflammatory cytokines (e.g. TNF-α, IL-6, IL-1) in the treatment 
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of cachexia. Animal model work has shown promising results but, as described above, 
models vary in the aetiology of the cachexia they seek to reproduce and do not always 
accurately reflect the complex reality of human disease.  
1.6.3.1 Individual cytokine targets 
IL-12 and IL-15 administration both individually reduce tissue wasting in tumour 
bearing animals, probably at least partly via reduction in IL-6(404-407). Equally, 
specific antibodies or receptor antagonists to TNF-α, IL-6, IL-1 and IFN-γ have all 
been effective in preventing or attenuating at least some aspects of cachexia in a 
variety of animal models(180;406;408-410). In contrast, human trials of therapies 
targeting individual cytokines have been small in number and invariably 
disappointing. Trials are limited by the expense of these medications and safety 
concerns over blocking vital cytokine functions. Anti-TNF-α therapy has been most 
thoroughly investigated, partly due to the proven safety record and widespread use of 
this medication in other inflammatory diseases such as arthritis and inflammatory 
bowel disease. Etanercept (Enbrel®) is a soluble recombinant fusion protein 
comprised of two TNF-R2 receptors bound to the Fc portion of human IgG1. Each 
etanercept molecule binds two TNF-α molecules, preventing them binding to the 
native receptor. Infliximab (Remicade®) and adalimumab (Humira®) are both 
monoclonal antibodies which bind and neutralise TNF-α. A small study added either 
etanercept or placebo to docetaxel chemotherapy in advanced cancer patients and 
found an improvement in fatigue in the etanercept group(411). In a trial of 89 patients 
with advanced pancreatic cancer patients were given standard gemcitabine therapy 
with either infliximab or placebo. There was a slight trend toward improvement in the 
QOL and LBM in the infliximab group but this did not reach significance(412). A 
similar trial using docetaxel +/- infliximab in poor performance non-small cell lung 
cancer patients was stopped early because the addition infliximab did not attenuate the 
weight loss(413). A placebo controlled trial of etanercept in cancer cachexia showed 
no clinical benefit(406) and two small trials of etanercept in breast and ovarian cancer 
have not shown definite clinical benefit(204;414). One small trial of anti-IL-6 
monoclonal antibody in patients with acquired immunodeficiency syndrome and 
lymphoma suggested a possible improvement in fever and body weight(415). 
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1.6.3.2 Pentoxyfylline 
Pentoxyfylline is a phosphodiesterase-4 inhibitor which reduces plasma levels of 
TNF-α by reducing its production by monocytes and T lymphocytes(416;417). It is 
widely used clinically for a variety of indications including intermittent claudication 
and alcoholic hepatitis. Again pentoxyfylline has been successful in preventing 
muscle atrophy in the yoshida-sarcoma bearing rat(418) but not in preventing human 
cachexia(419). It is interesting that pentoxyfylline is ineffective in the treatment of 
Crohn’s disease despite the enormous success of other anti-TNF-α therapies in that 
situation.  
1.6.3.3 Eicosapentaenoic acid (EPA) 
EPA is an alpha-3 omega fatty acid found in fish oil. It down-regulates pro-
inflammatory cytokines, PIF, the UPP(420;421) and protein catabolism(422) in 
murine models. It prevents cachexia in Walker 256 tumour-bearing rats(423) and 
protects otherwise healthy rats from the cachexia-like symptoms induced by 
starvation(424) or IL-1 administration(242). The first major study of EPA in human 
disease suggested that adequate amounts led to increases in lean body mass and 
quality of life(425). Unfortunately two follow up trials, one by the same group, failed 
to replicate the positive results(426;427). 
1.6.3.4 Cyclooxygenase-2 (Cox-2) inhibitors  
Cyclooxygenase-2 inhibitors block the synthesis of prostaglandin from arachidonic 
acid. This leads in turn to a reduction in TNF-α and IL-6 expression. Animal studies 
using a number of different models have demonstrated an anti-cachexic effect(428-
430). Small human trials using COX-2 inhibitors alone are also promising(366;431) 
(REFS 15,16,17). McMillan gave either megesterol acetate alone or megesterol 
acetate with ibuprofen (a COX-2 inhibitor) to patients with advanced gastrointestinal 
cancer and weight loss. There was a weight reduction in the megesterone acetate 
group and a weight increase in the group taking ibuprofen in addition, leading to a 
significant difference between groups(432). Mantovani led an interesting non-
randomised study in which 39 patients with advanced cancer were given a 
combination of celecoxib (a COX-2 inhibitor), medroxyprogesterone acetate, and 
nutritional support including EPA supplementation. The combination seemed 
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effective in reducing TNF-α and IL-6, fatigue and REE and increasing appetite, LBM 
and QOL(433). He went on to show that celecoxib alone improved LBM and reduced 
TNF-α in cancer cachexia(434)  
1.6.3.4.1 Direct UPP inhibitors 
Bortezomib (Velcade®) binds specifically with the 20S proteasome complex, so 
blocking the UPP. A study of 46 patients with advanced pancreatic cancer showed no 
benefit in single agent bortezomib therapy(256) and a trial of bortezomib, paclitaxel 
and carboplatin in advanced oesophageal or gastric cancer was closed early due to 
lower than expected chemotherapy response rates(435) 
1.6.3.5 Metabolic therapies 
1.6.3.5.1 Hydrazine sulphate 
Hydralazine is a cori-cycle inhibitor but three placebo-controlled trials have shown no 
benefit in cancer cachexia(436-438) and side effects can be serious(439). 
1.6.3.5.2 Insulin 
One human study using insulin therapy in 138 patients with advanced gastrointestinal 
malignancy showed some measureable metabolic improvements (although no increase 
in lean body mass or significantly improved survival in the insulin treated 
patients(440).  
1.6.4 Miscellaneous 
The search for a successful treatment for cachexia has seen infusions of adenosine 5’-
triphosphate (ATP) leading to improvements in lean body tissue and survival in 
advanced non-small cell lung cancer(441-443) and melatonin (which down-regulates 
TNF-α(443)) attenuating cachexia and improving survival in advanced non-small cell 
lung cancer(444;445), although in other cancer trials this it has not been 
successful(365). Many other substances have been trialled but with limited or no 
success. 
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 Thalidomide 
Thalidomide was originally marketed in 1956 as a sedative, relaxant and anti-emetic 
for pregnancy associated nausea. It was however withdrawn from the European 
market in 1961 following a relatively high incidence of previously rare limb 
abnormalities in children born to women who had taken the drug, even in very small 
amounts, during their pregnancies. In all approximately 10,000 people were affected. 
During this time the US Food and Drug Administration (FDA) did not approve it due 
to concerns over long term side effects. In 1965 it re-emerged as a treatment for 
erythema nodosum leprosum (ENL)(446), a painful, vasculitic complication of 
leprosy, gaining FDA approval for this indication in 1998. During these last three 
decades the only noted major side effect for the non-pregnant patient has been an 
infrequent peripheral neuropathy which occurred in 3 out of 49 patients treated for six 
months in one study(447) and in 1 out of 23 patients in another(448). Renewed 
interest was stimulated in 1991 by the discovery of thalidomide’s powerful in vitro 
suppression of TNF- production from lipopolysaccharide stimulated 
monocytes(449), exerting its effects by enhancing degradation of its mRNA(450;451). 
Subsequent work has shown thalidomide to modulate several other factors including 
IFN-, IL-10, IL-12, cyclooxygenase 2 (COX-2)(452). It also blocks TNF- and IL-
1 activation of NFκB(253). This is at least partially the basis for its well documented 
immunomodulatory and anti-inflammatory properties(453;454). Previous studies have 
found thalidomide to be effective in the management of a wide variety of clinical 
conditions, including HIV associated wasting(455) and the weight loss experienced in 
pulmonary tuberculosis(456). 
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Figure 14 Effects of thalidomide on TNF-alpha.  
 
Figure 15 The proven effect s of thalidomide in cachexia (in orange) are mainly directed towards 
the TNF alpha mediated processes 
 
 
There has recently been a great deal of interest in the use of anti-angiogenic agents as 
adjuncts to standard chemotherapy in both haematological and solid organ 
malignancies. Bevacizumab (a humanised monoclonal antibody directed against 
vascular endothelial growth factor) was the first angiogenesis inhibitor to market after 
it was given US FDA approval for use as a first-line treatment for patients with 
metastatic colorectal cancer in 2004. Thalidomide is known to be anti-angiogenic, 
possibly by reducing NFκB mediated production of IL-8, a required cytokine for 
angiogenesis(253) or possibly through inhibition of VEGF. It has been shown to 
inhibit VEGF secretion in cell lines in vitro(457) and depletes VEGF receptors in 
zebra fish embryos(458) but does not affect local VEGF increases after liver injury in 
rats(458;459). This anti-angiogenesis led to trials into its use as an anti-cancer agent. 
At present, few phase III trials have been completed but data suggest a benefit in 
multiple myeloma(460), refractory Waldenström’s macroglobulinaemia(461), 
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myelodysplasia(462), advanced prostate cancer(463), renal-cell carcinoma(464), high-
grade glioma(465), melanoma(466) and colorectal cancer(467), in some instances 
resulting in reduction of tumour bulk. Thalidomide is approved in some countries for 
the treatment of multiple myeloma after the failure of standard therapies and the acute 
treatment of cutaneous manifestations of moderate to severe ENL. It has been shown 
that the response rate in multiple myeloma cannot be explained only by the reduction 
of angiogenesis(468). It is possible that some of the anti-tumour effect is mediated by 
thalidomide’s inactivation of NFκB, which is known to activate the expression of 
genes involved in cell growth and suppression of apoptosis(249;253). Thalidomide 
also reduces production of Cox-2(452), which is thought to play an important role in 
cancer therapy through angiogenesis, immune surveillance and apoptosis(469). In 
metastatic, chemotherapy resistant colon cancer, the addition of thalidomide to 
irinotecan chemotherapy improved response rates from 12-21% to 29%. 
Thalidomide’s sedative and anti-emetic effects also allowed patients improved 
toleration of the irinotecan(470). Phase III studies are currently in progress. 
Lenalidomide is a thalidomide analogue with similar but more potent effects and a 
more favourable toxicity profile (less constipation and neurotoxicity). In many cases it 
is now prescribed as an alternative to thalidomide. 
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Figure 16 Known actions of thalidomide in cancer 
 
Figure 17 Thalidomide also has direct effects (in orange) on the processes governing the growth 
and spread of cancers 
 
 Previous clinical trials of thalidomide in cancer 
cachexia 
To date there are five published human trials evaluating the use of thalidomide in 
cancer cachexia. Bruera(471) showed in an uncontrolled study involving 37 patients 
with terminal malignancy that thalidomide’s anti-emetic, analgesic, and sedative 
properties were effective in the palliation of otherwise intractable symptoms in 
patients with terminal malignancy. Khan et al.(472) have reported an open label pilot 
study of thalidomide in the treatment of cachexia in eleven patients with inoperable 
oesophageal cancer. In this study thalidomide reversed weight loss over the two week 
period of the trial, and this was associated with an increase in lean body mass. The 
same group went on to randomise 16 end stage oesophageal cancer patients to 
thalidomide and 16 patients to placebo. They found thalidomide to be poorly tolerated 
due to skin rashes, hyper-somnolence, paraesthesia, constipation, headache and 
neutropenia. They were not able to demonstrate any benefit from the treatment. 
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Our research group published the results of the first randomised placebo controlled 
trial of thalidomide in the treatment of cancer cachexia(454). In this study we 
demonstrated that thalidomide is safe and effective in attenuating weight loss in 
patients with cachexia secondary to advanced pancreatic cancer. In this study 50 
patients were recruited to either thalidomide (200mg per day) or placebo. Of these 33 
patients (17 thalidomide, 16 placebo) were available for assessment at four weeks and 
(12 thalidomide, 8 placebo) at eight weeks. At four weeks, those who received 
thalidomide had gained on average 0.37 kg in weight and 1.0 cm3 in arm muscle mass 
(AMA) compared with a loss of 2.21 kg (absolute difference 22.59 kg [95% 
confidence interval (CI) 24.3 to 20.8]; p = 0.005) and 4.46 cm3 (absolute difference 
25.6 cm3 [95% CI 28.9 to 22.2]; p = 0.002) in the placebo group. At eight weeks, 
patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm3 in AMA 
compared with a loss of 3.62 kg (absolute difference 23.57 kg (95% CI 26.8 to 20.3); 
p = 0.034) and 8.4 cm3 (absolute difference 27.9 cm3 (95% CI 214.0 to 21.8); p = 
0.014) in the placebo group. Improvement in physical functioning correlated 
positively with weight gain (r = 0.56, p = 0.001). 
 
 
Figure 18 The change in weight seen in pancreatic cancer patients randomised to either 
thalidomide or placebo in our previous trial 
 
Thalidomide n=17 week 4, n=12 week 8; Placebo n=16 week 4, n=8 week 8. Between 
groups p=0.005 at 4 weeks, and 0.034 at 8 weeks. 
 
The general weight loss correlated with a reduction in loss of lean body mass as 
measured by anthropometric techniques. There was also a trend towards prolonged 
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life expectancy with a median survival of 148 days in the thalidomide group 
compared to 110 days in the placebo group. This survival benefit is similar to that 
seen in recent trials using gemcitabine as single agent chemotherapy. The thalidomide 
was well tolerated; two patients (9%) complained of peripheral neuropathy that 
resolved on stopping the drug, and two patients (9%) developed a rash that 
necessitated withdrawing from the trial. A further four patients (17%) complained of 
severe daytime somnolence that required a reduction in drug dosage in two patients, 
and cessation of the drug in the other two. Conversely, those in the placebo arm 
suffered significantly more from insomnia (p=0.023). Constipation was the only other 
side effect experienced to significant levels (p=0.04). Further studies are required to 
investigate whether it is possible to generalise these results to cancer cachexia caused 
by other cancers, and whether there is a true survival benefit. There is also a lack of 
human data on the underlying biological processes of this condition and the effect 
thalidomide has on these. 
 
Mantovani ran a complex phase III trial randomising 332 patients with advanced 
cancer and loss of >5% of their ideal or pre-illness body weight to five different 
therapy arms: 1 progestagen; 2 EPA; 3 L-carnithine (an amino acid derivative 
involved in transporting long chain fatty acids to mitochondrial for energy 
production); 4 thalidomide 5 progestagen + EPA + L-carnithine + thalidomide. Arms 
1 (progestagen) and 2 (EPA) were stopped after interim analyses demonstrated 
inferiority. All treatments were well tolerated and patient compliant was good. 
Thalidomide resulted in a significant reduction in IL-6, Glasgow Prognostic Score 
(GPS) and ECOG PS with no adverse effects. The combination arm (5) was the most 
effective for all measured end points: IL-6, TNF-α, GPS and ECOG PS.  
 Measurement of lean body mass 
One of the major obstacles into cachexia research has been measurement of lean body 
mass. There are accurate techniques available, for example underwater weighing or 
isotope dilution but all involve expensive or bulky equipment and are not practical 
outside a laboratory research setting. Anthropometric techniques such as measurement 
of weight, triceps skin fold thickness, mid-arm circumference are simple and 
validated but have an average error of around 7-8%(473). Dual-energy x-ray 
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absorptiometry (DEXA) scanning uses X-rays of two energy levels that are attenuated 
by different tissues to different extents to offer a precise and non-invasive method 
which makes no assumptions of the chemical constancy of lean tissue mass(474-476). 
It is however expensive, involves a small radiation dose and necessitates immobile 
equipment. Bio-impedance is a widely used but relatively new technology that relies 
on mathematical equations validated in specific patient groups to determine body 
composition data from raw bioimpedance values. The bioimpedance value is largely 
influenced by the type of tissue the current is travelling through (e.g. fat, water, 
muscle) but will also be influenced by other factors such as extracellular water and 
cell membrane integrity. Bio-impedance is relatively cheap, portable, easy to use and 
safe. Equations have been validated in many varying patient groups but not 
specifically for cachectic patients who will have inevitable changes in electrolyte 
composition, body water compartmentalisation and cell membrane integrity(477;478).  
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Chapter 2 Aims and Objectives 
 Aims 
Based on our previous work we hypothesised that thalidomide can attenuate or 
reverse both total weight loss and loss of lean body mass in the cachexia associated 
with incurable upper gastrointestinal adenocarcinomas. 
 
In addition we wished to investigate whether this was associated with an improved 
quality of life or survival benefit; to obtain a profile of the serum factors implicated in 
the development of cachexia and investigate how these are affected by thalidomide 
and to obtain a safety profile for thalidomide in this patient group. 
 Objectives 
2.2.1 Primary objectives 
To evaluate the ability of thalidomide, as compared to a placebo, to attenuate loss of 
weight in patients with incurable upper gastrointestinal adenocarcinomas. 
2.2.2 Secondary objectives 
1. To assess any impact on functional or overall quality of life 
2. To calculate any change in overall survival. 
3. To calculate any change in lean muscle mass 
4. To calculate any change in grip strength 
5. To obtain serum profiles of factors previously implicated in the development 
of cachexia for both the control and treated group 
6. To document the safety and tolerability of thalidomide in patients with 
incurable upper gastrointestinal adenocarcinomas. 
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Chapter 3 Patients, materials 
and methods 
 Trial type 
This was a non-commercial, NHS sponsored double-blind, placebo controlled clinical 
trial. A placebo was chosen for the control group as there is no currently accepted 
standard or effective treatment for cachexia. The trial period for each patient was six 
months. 
 Trial conduct and sites 
Patients were recruited from 7 sites across London and the South of England between 
December 2005 and February 2011. 
The study protocol was approved by Southampton and South West Hampshire 
Research Ethics Committees(B) in Aug 2005; by the Medicines and Healthcare 
Products Regulatory Agency in September 2005; by the Research and Development 
Management committee of each individual site and registered with the International 
Standard Randomised Controlled Trial Number Register (ISRCTN51456701). 
Twice during the trial un-blinded results were reviewed by an Independent Trial 
Monitoring committee. 
 My own role in the trial 
I conceived, set up and ran the trial as Chief Investigator. I successfully gained ethics, 
and MHRA approval, funding and drug supply as well as taking responsibility for all 
aspects of trial management. I also developed the laboratory assays and ran the 
samples. 
 Participants 
Patients over the age of 18 years with incurable upper gastrointestinal 
adenocarcinomas and weight loss of over 5% of their pre-morbid weight or actively 
losing at least 1kg per month were identified at gastroenterology or oncology clinics 
or through multidisciplinary team cancer meetings. The diagnosis was required to be 
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confirmed cytologically or histologically other than in pancreatic cancers where 
biopsy is often technically difficult and uncomfortable, in these patients the diagnosis 
was accepted if felt to be unequivocal clinically and radiologically. Patients were not 
be recruited within four weeks of receiving either chemotherapy or radiotherapy. 
Those with clinically detectable ascites or oedema were not included due to 
potentially complicating weight measurements. Those with evidence of peripheral 
neuropathy, severe constipation, vertigo or vestibular disease were not included due to 
known potential thalidomide toxicity. Premenopausal women were included but 
required to comply with strict guidelines and submit a monthly pregnancy test. Those 
using megesterol acetate at a stable dose for at least a month were included but asked 
not to adjust their dose during the trial. Use of corticosteroids and nutritional 
supplements was unrestricted but documented at clinic visits. 
 Sample size 
The sample size to detect a 2kg difference in weight change between the two groups 
at 4 weeks, assuming a between subject standard deviation of 4.3 (based on our 
previous study(479)) with 80% power required 74 subjects per treatment group. 
Allowing for 20% attrition we planned to recruit a total of 90 subjects per group.  
Initially the trial was planned as a single centre. Analysis of eligible patients over the 
previous three years and our experience of the proportion of patients agreeing to 
participate in our previous trial suggested that the trial should be fully recruited within 
18 months. The launch of the trial coincided with a dramatic change in practice in 
non-curable upper gastrointestinal cancer patients. During recruitment for our 
previous trial there were no other worthwhile medical treatments available and 
patients were generally given trial information at the same outpatient appointment at 
which they were told their diagnosis. Gemcitabine was licenced for palliative use in 
terminal pancreatic cancer in 2001(480) and became common practice at our and 
many other institutions around the time of the launch of this trial. This dramatically 
reduced the pool of patients with no other acceptable options available to them. It also 
meant that it was generally inappropriate to recruit to the trial at the first outpatient 
appointment as time was required for the patient to consider their, now very real, 
options. If they even wanted to consider gemcitabine therapy they were required to 
have a biopsy which would generally take about 2-3 weeks to be taken and analysed. 
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In many cases, by the time gemcitabine had been considered and sometimes tried but 
rejected, patients who would previously have been ideal candidates for the trial were 
either ineligible due to a life-expectancy now less than the required 8 weeks or had 
simply had enough of medical intervention and were not interested in even 
considering participating. It was also a considerable challenge to identify patients who 
may be eligible for the trial in the future and keeping track of their progress until such 
a time as they were appropriate for consideration. Consequently recruitment was 
substantially slower than anticipated. The planned single centre trial was extended to 
a total of seven sites in an attempt to reach the required sample size but the trial was 
eventually closed due to slow progress when 63 participants had enrolled. 
 Trial intervention 
Each subject was asked to take thalidomide 200mg (a dose used by ourselves and 
others in previous studies(471;472;481)) or identical placebo once every evening for a 
period of 26 weeks. Thalidomide is prepared in capsules of 50mg, this therefore 
entailed taking four capsules per day. Participants were asked to take all four capsules 
just before bedtime to reduce somnolence but after recruitment of 46 patients, it was 
noted that drowsiness after the initial dose was limiting tolerance in some patients. A 
protocol amendment was therefore made and from that point participants were asked 
to take one capsule on the first day and then increase by 50mg each day until taking 
the full 200mg or their maximum tolerated dose, whichever was the lesser. If side 
effects were troublesome to the patient and not easily controlled by conventional 
means (e.g. anti-emetics or laxatives) then the dose was reduced to 100mg, if they 
continued despite dose reduction the drug was stopped and the patient was withdrawn 
from the trial. Drug compliance was assessed by direct questioning and pill count at 
each patient visit. 
 
Thalidomide 50mg capsules and identical placebo were manufactured by Penn 
Pharmaceuticals Services limited, Tredegar, Gwent NP22 3AA and supplied free of 
charge from Pharmion Ltd, Riverside House, Riverside Walk, Windsor, Berkshire 
SL4 1NA (now Celgene Corporation, 86 Morris Avenue, Summit, New Jersey, USA).   
The drug was supplied in 28 capsule blister packs labelled with the contact details of 
the co-ordinating investigator and ‘for clinical trial use only’. The placebo capsule 
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and packaging was identical to the active medication in every way other than that it 
did not contain the active ingredient (thalidomide). At each visit patients were 
supplied with enough capsules from their allocated box to last until their next 
appointment. Patients were asked to return any surplus drug and this was disposed of 
through the hospital pharmacy. 
 
We were able to continue to supply trial medication after the 6 month period for 
patients who wished to continue to take it. Only after careful discussion with each 
individual patient with consideration of potential long-term side effects (peripheral 
neuropathy in particular) was this considered. Full details of thalidomide’s 
international licensing are contained in the Investigator’s Brochure. 
 Randomisation process 
Medication was supplied by the manufacturing company in blocks or four, each 
consisting of supply for two participants on active drug and two on placebo. Enough 
drug for each subject for the six month course of the trial was boxed and labelled from 
1-180 to correspond to individual patient trial numbers. The sequence was generated 
by a standard computerised randomisation procedure at the manufacturing site. 
Stratification was applied for pancreatic and non-pancreatic origin because previous 
trial information related to pancreatic alone and we were keen to be able to analyse 
these results separately, also because the prognosis of pancreatic cancer is generally 
poorer than other upper gastrointestinal cancers. Stratification was also applied for 
trial site. Each trial site held two blocks of four at any time, one for pancreatic patients 
and one for non-pancreatic. Once a block of four was started, it was completed with 
patients of the appropriate primary cancer site (pancreatic or non-pancreatic) and at 
the same trial site. Prior to a block of four being completed a further block of four 
would be allocated and delivered to that trial site. Packaging of active drug and 
placebo was identical, keeping the investigators, pharmacists and patients blind to the 
allocation. New participants were simply allocated the next available number in the 
appropriate block. 
 
The medication was supplied in bulky boxes meaning that the handling pharmacy at 
the Queen Alexandra Hospital could only accept relatively small batches due to 
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volume storage restrictions. The drug was short dated and an agreement was made 
with the pharmaceutical supplier (Pharmion ltd) that unfinished blocks would be 
replenished when necessary to allow them to be completed. Unfortunately Pharmion 
was taken over by Celgene just after the trial launched and on two occasions supplied 
new drug as new blocks of four rather than replenishments for uncompleted blocks. 
Had recruitment been completed, this would have been of no consequence but due to 
the sub-optimal number of participants, meant that they were scattered through the 
planned blocks of four with resulting uneven spread between groups. 36 were 
allocated active medication and 27 to placebo. 
 Schedule of events 
Trial visits were conducted at baseline, 1 month, 2 months, 3 months and 6 months. 
All subjects were given the opportunity to see a dietician for general nutritional 
advice. Patients were contacted by telephone at 7 months and questioned about any 
adverse events. At each trial visit any adverse events were recorded using the 
Common Terminology Criteria for Adverse Events (CTCAE) system(482) Any new 
symptoms were explored with details concerning time of onset, action taken and 
outcome. A neurological examination was conducted and sensation to pinprick, light 
touch, vibration and proprioception documented. All clinical measurements were 
taken (see 3.9). Bloods were taken at baseline, 1 month, 3 months and 6 months 
(visits 1, 2, 4 and 5).  
 
Patients developing symptoms or signs of peripheral neuropathy or neutropenia with 
less than 500 cells/mm3 was withdrawn from the trial. Patients requiring 
chemotherapy or radiotherapy after trial enrolment was be withdrawn from the study. 
No patient was replaced. 
 
Table 2 Schedule of events 
Events 
Initial clinic 
appointment 
Month 
0 
Month 
1 
Month 
2 
Month 
3 
Month 
6 
Month 
7  
Visit number 0 1 2 3 4 5 Home 
Week 
 
 
0 4 8 12 26 
30 
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Assess 
eligibility 
      
 
Give 
information 
sheet 
      
 
Informed 
consent 
      
 
Randomisation        
Detailed history        
Blood sample        
Neurological 
exam  
      
 
Anthropometry        
Bio-impedance        
DEXA scan  As opportunity arises 
QOL 
questionnaire 
      
 
Prescribe 
medication 
      
 
Check 
compliance 
      
 
Record adverse 
events 
      
 
Pregnancy test        
Phone call for 
adverse effects 
      
 
 
 Clinical measurements 
All equipment was used according to the manufacturer’s instruction manuals. All trial 
practitioners involved in taking the clinical measurements were trained by the same 
investigator.  
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3.9.1.1 Grip strength 
Grip strength was measured in the non-dominant hand to detect smaller changes more 
easily. Measurements were taken in triplicate with the average reading being taken. A 
Jamar Hydraulic Hand Dynamometer was used for grip strength evaluation due to its 
proven accuracy(483) and robust and portable design. 
 Lean Body Mass 
We chose to use anthropometry, bioimpedance and DEXA scanning to assess LBM. 
We were aware that only a proportion of patients would be able to undergo DEXA 
imaging as it was only available to us at the Queen Alexandra Hospital. We presented 
the DEXA to the participants as an additional voluntary investigation that was not part 
of a standard clinic visit as it required extra time and a walk to radiology. We were 
sensitive to the possibility of this putting people off attending visits at all when all our 
other investigations were quick and simple. We hoped that obtaining comparative 
DEXAs for even a proportion of the anthropometry readings would allow us to judge 
the accuracy of these two other portable methods in our patient population.  
3.10.1.1 Weight  
Measured without shoes and wearing light clothing only 
3.10.1.2 Anthropometry 
Mid upper arm circumference (MAC) was measured using stretch resistant tape  
Triceps skin-fold thickness (TSF) was measured using Harpenden skinfold callipers – 
(the only caliper CE marked under the Medical Devices Directive 93/42/EEC for a 
Class 1 device with measuring function) 
Bone free arm muscle area (AMA), a validated marker of lean muscle mass, was then 
be calculated from MAC and TSF using the formula (MAC - πTSF)2 / 4π minus a 
correction factor of 10 for male sex or 6.5 for female sex(473). 
3.10.1.3 Bioimpedance 
We chose to use a tetrapolar multi-frequency machine (Bodystat® Quadscan 4000 
Multi-frequency Bioelectrical Impedance Analyser) for optimised accuracy(484-486). 
Measurements were taken according to the manufacturer’s instructions in the supplied 
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manual and data was interpreted using standard equations on commercial software 
from Bodystat® Ltd 
3.10.1.4 DEXA 
Dual-energy X-Ray absorptiometry (DEXA) scanning was only available at one study 
site using a Hologic Discovery A Model scanner. 
3.10.2 Quality of Life 
Quality of life was measured using the EORTC QLQ-C30 questionnaire(487) and 
analysed using the published scoring manual(488). The questionnaire is composed of 
30 questions. Each assesses either functional capacity, symptomatology or overall 
global health. There is no overlap, with the answer to each question then being 
analysed in only one of the three scales. 
The functional scale is composed of questions 1-7 and 20-27; symptom scale 
questions 8-19 and 28; and global health score questions 29 and 30. 
  
The raw score given by the patient on the functional questions will give a higher score 
with increased difficulty carrying out activities, a higher score therefore representing a 
lower level of functioning. In the symptom questions the higher the raw score the 
more unpleasant symptoms the patient is reporting and for global health score the 
higher the score the better the overall reported quality of life.  
 
The following linear transformations were therefore applied to convert the raw score 
into a standardised score from 1-100 where a higher score represented a higher 
response level(488).  
Functional Standardised score = (1-(raw score-1/range))x 100 
Symptoms Standardised score = (raw score-1/range)x 100 
Global 
Health 
Standardised score = (raw score-1/range)x 100 
 
After transformation a higher score represents: 
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Functional a higher, more healthy functional level. An improvement in 
functioning will equate to an increase in the standardised functional 
score 
Symptoms a higher, less healthy amount of symptomatology. An improvement in 
symptoms will equate to a reduction in the standardised symptom 
score 
Global 
Health 
an improved quality of life. Improvements in quality of life will equate 
to an increase in the standardised global health score   
 Laboratory Measurements 
3.11.1 Collection of blood samples 
Sterile collection of blood samples was undertaken by venepuncture using 
Vacutainer® passive shielding blood collection needles. Blood for measurement of 
full blood count, urea and electrolytes, liver function tests, thyroid function tests, 
albumin and C-reactive protein (CRP) was drawn into the standard bottles used at that 
hospital site. Blood for cytokine estimation and retrieval of monocytes and 
lymphocytes was drawn into 7.5ml S-monovette containers containing 1.6mg ETDA 
for anti-coagulation (Sarstedt, Germany). These tubes were selected because they are 
compatible with Vacutainer® needles and are guaranteed to be free of pyrogens 
including endotoxin (which has been previously shown to affect cytokine levels, 
particularly TNF-α)(489;490). 
 
Full blood count, urea and electrolytes, liver function tests, thyroid function tests, 
albumin and CRP were measured through the standard hospital system at each 
individual trial site on fresh samples. 
 
Samples for cytokine estimation and monocyte / lymphocyte estimation were put on 
ice immediately and processed within 2 hours to avoid cytokine breakdown(491), 
particularly TNF-𝛼, which is known to deplete in samples stored at room temperature 
or for prolonged periods of time(492). The Monovette container was centrifuged at 
1000g for 10minutes. The plasma layer at the top of the sample was then carefully 
removed using a sterile Pasteur pipette and separated into 500μl aliquots prior to 
freezing at -800c and stored at that temperature until analysis. Evidence suggests that 
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cytokine levels including TNF-α are resistant to freeze-thaw cycles(493) but these 
were avoided none the less.  
 
 
Figure 19 Standard Operating Procedure for processing blood samples. This was provided to the 
trial nurses at each site after one to one training sessions 
3.11.2 Enzyme-linked immunosorbent assays 
(ELISAs) 
We measured levels of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 to 
investigate any links between peripheral levels and clinical findings. Both TNF-α and 
IL-1β(300) have proven difficult to detect by previous investigators as they are 
present at low levels in the serum and TNF-α in particular seems sensitive to 
collection and storage technique. We therefore also performed ELISAs for TNFR2 
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and IL-1ra as surrogate markers(300). We measured VEGF levels as a marker of 
angiogenesis.  
 
All cytokine levels were measured using sandwich ELISAs. One of the major 
difficulties was the measurement of TNF-α in human plasma. Previous authors have 
shown a significant difference in the results obtained by commercial kits available 
from different companies and often low serum levels have been undetectable(494-
496). We therefore chose to develop our own ELISA for each analyte rather than use 
a commercially available kit to allow us to optimise the technique in order to detect 
very low levels, particularly of TNF-α. The basic sandwich ELISA used was a 
combination of that recommended by RnD Systems(497) and that developed from 
previous experience in our laboratory (with special thanks to Marta Polak). Previous 
authors have published studies attempting to improve the sensitivity of TNF ELISAs 
in human plasma(498;499). Our method was based on that described by Kittigul, 
taken from his original paper and on the work of Innis et al.(500-502). 384 well 
microplates were used throughout (rather than the standard 96 well) so that all 
samples could be fitted onto one plate with room for control lines with serum spiked 
with recombinant standard on the same plate to improve accuracy. Microplates were 
coated with a capture antibody specific to the analyte of interest. Blocking buffer was 
then added to block all unbound sites on the microplate, thereby preventing later non-
specific binding of detection antibody or horseradish peroxidase (HRP) and so 
reducing background noise. The sample was then added causing the analyte to be 
indirectly bound to the plate by the capture antibody. A second antibody was added 
which binds to a different epitope of the analyte and is itself labelled with biotin, 
completing the sandwich. The biotin tag was then labelled with HRP which has an 
extremely high affinity for biotin and so enhances the signal increasing low level 
detectability. Luminol was then added. HRP oxidises luminol to 3-aminophthalate 
emitting light proportional to the amount of analyte present. The emitted light was 
quantified in relative light units (RLUs) using a luminometer. This 
chemiluminescence method has been proven by others capable of detecting analyte at 
very low concentrations(503). All antibodies and standard proteins were purchased 
from RnD systems ltd and the dilutent used to reconstitute each individual analyte 
were as recommended from the manufacturer. Washes between steps were with 
phosphate buffered saline (PBS, Sigma-Aldrich®) – a formulation of buffers and slats 
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which is isotonic and aids in maintaining a constant pH at 7.4. 0.05% tween was 
added to all washes as a detergent to reduce background. ELISA grade Bovine Serum 
Albumin (BSA) was used as the blocking agent to prevent non-specific binding of the 
antigens and antibodies to the microplate. Sodium azide (NaN3 0.08%) was added as a 
biocide to all dilutents until the detection stage to prevent bacterial contamination. 
Repeated runs of the TNF-α ELISAs showed the signal (the luminescence from the 
standard containing cells) to noise (the luminescence from the cells containing 0% 
standard) ratios were consistently better without NaN3 so it was not used for TNF-α 
ELISAs. NaN3 works by stopping peroxidase working and so affects HPR which 
could have caused the problem, although it seemed to benefit all other ELISAs by 
reducing background and should be completely washed from the microplate prior to 
adding HRP. All washes and dilutents were produced by hand fresh just prior to use to 
prevent contamination. 
 
Before any patient samples were processed, the ELISA standard operating procedure 
(SOP) for each individual analyte was optimised. Initially the ELISA technique was 
used to find the most effective dilution combination of the capture and detection 
antibodies using a checkerboard technique: 
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Figure 20 Checkerboard technique used for ELISAs 
Capture in ug/ml 
100% 50% 100% 50% 
             100% Detectio
n
 in
 u
g
/m
l 
            50% 
            25% 
  
Standard 
100% 
    
Standard 
50% 
  12.5% 
        6.25% 
            3.125% 
            1.5625% 
            0 
            0 
            1.5625% 
  
Standard  
10% 
    
Standard 
0% 
  3.125% 
        6.25% 
            12.5% 
            25% 
            50% 
            100% 
 
Graphs were plotted of the results. These were used to select the concentrations 
producing the best signal to noise ratio. Once the optimum antibody concentrations 
had been established the ELISA was run multiple times for each analyte, altering 
various factors such as incubation times, BSA product, with or without NaN3. Once 
the ELISA was optimised it was re-run using serial dilutions of spiked serum from 
healthy volunteers to minimise matrix effects. A checkerboard style to establish the 
optimal dilution for the final run using patient samples. The dilutent used was always 
identical that used to prepare the standards for the specific analyte. Trials runs using 
serum usually used my own as I found it to have undetectable levels of all pro-
inflammatory cytokines on every trial, possibly due to a coincidental pregnancy.  
 
Once ELISA SOPs had been established, each sample was analysed for analysed for 
TNF-α, sTNF RII, IL-6, IL-1b, IL1RA and VEGF,. Each sample was analysed in 
triplicate and the mean of the three samples used. Because the trial was prolonged, 
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samples were stored at -800c for up to five years. Freeze thaw cycles were avoided by 
dividing the original sample into small (0.5ml) aliquots prior to the initial freeze. All 
samples available in 2006 were analysed at that time. Different aliquots of the same 
samples were re-analysed with all samples in 2011 and these were the results 
presented. Coefficients of variation (CV) between repeat determination of identical 
samples in 2006 and 2011 were all under 15 and highly correlated (p<0.001) 
suggesting the storage was effective in keeping specimens stable and adding validity 
to our ELISA SOP. Softmax pro® was used to plot standard curves and interpret 
serum samples. For ELISA results below the limit of detection the extrapolation 
method was used as this is recommended as the most accurate method. Results below 
the limit of extrapolation were classed as zero(504). Mean coefficient of variation for 
the final results run were TNF-α 12.3, sTNF RII 3.4, IL-6 3.7, IL-1b 12.83, Il-RA 6, 
VEGF 3.6.  
 
Full details of the establishment of the ELISA in appendix 8.1. The full IL-6 SOP is 
presented in appendix 8.4. 
 
 Survival 
While actively involved in the trial dates of death were noted in the trial case report 
forms. For those who survived past the end of the trial survival was monitored using 
the hospital computer system with phone calls to the patient’s general practitioner for 
clarification if necessary 
 End of Trial 
The end of the trial was defined as the last phone call to the last patient. After the end 
of the trial survival times were monitored through the hospital or general 
practitioner’s records. 
 Statistical analysis 
Analysis was performed on an intention to treat basis. Demographic data was 
interpreted using Fisher’s Exact Test for categorical data, the Mann-Whitney Test for 
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ordinal or skewed data and the independent samples t-test for normally distributed 
continuous variables.  
 
Comparison of methods for measuring lean body mass was made by correlating the 
results, comparing the average difference with the paired samples t-test and by 
assessing the agreement between methods using the Bland Altman and intra-class 
correlation coefficient (ICC) methods. The Bland Altman limits of agreement method 
was chosen to analyse size of differences between pairs. In this the measure is 
obtained by first calculating the difference between the methods for each individual 
observation. The 95% limits of agreement (within which 95% of all differences 
between methods should occur) are then calculated as follows:  
Mean difference +/- 1.96(standard deviation of the differences) 
 
The ICC method examines the total variability in outcome values and divides it into 
two components: that due to patient differences and that due to difference between 
methods for the same patient. The ICC value is the proportion of the difference which 
is due to between patient differences. If there is good agreement between methods 
then the ICC value will be close to 1. This can be calculated on SPSS using an 
‘absolute agreement’ option, meaning the values should be identical, or using a 
‘consistency’ option meaning there is a consistent linear relationship even if the 
absolute values are not identical. We felt this was reasonable for our purposes and 
used the ‘consistency’ option. 
 
The Quality of Life Questionnaire used produces results in three domains: Global 
Health Score, Functional scales and Symptom scales. Results from each section were 
analysed as well as ‘physical functioning’, a subdivision of the functional scale which 
we felt to be particularly relevant(482). Results were transformed into standardised 
scores (see quality of life methodology, section 3.10.1.4) and analysed as 
recommended in the EORTC QLQ-c30 Scoring Manual (488). Results were 
compared using the independent samples t-test.  
  
The independent samples t-test was also used for comparison of clinical data between 
groups other than frequency of adverse events. Because the number of these was 
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small the Fisher’s Exact Test was used to compare groups. Kaplan Meir was used to 
analyse survival data. 
 
Due to the skewed results, Spearman’s rank correlation was used to compare cytokine 
levels between groups. 
 
A significance level of 0.05 was used throughout other than when multiple similar 
comparisons were made, when a Bonferroni correction was applied. 
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Chapter 4 Results 
 
 Patient flow 
Figure 21 Patient flow 
 
 
Of the 38 patients who withdrew during the course of the trial, the most common 
reason (20 patients) was a general physical deterioration or change in circumstance 
(e.g. being admitted to a hospice) leading to withdrawal of active or unnecessary 
treatment. Mean survival in the group that withdrew was 33 days after leaving the 
63 patients 
recruited
Thalidomide
visit 1 - 36 pts
visit 2 - 25 pts
visit 3 - 14 pts
vist 4 - 10 pts
visit 5 - 4 pts
4 died
4 withdrew 2 died
1 protocol 
violation
3 died
8 withdrew 3 died
8 withdrew 3 died
Placebo
visit 1 - 27 pts
visit 2 - 17 pts
visit 3 - 8 pts
visit  4 - 6 pts
visit 5 - 6 pts
6 died
0 withdrew 0 died
1 withdrew 1 died
8 withdrew 1 died
9 withdrew 1 died
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trial (median 25 days). Anecdotally, many wondered whether they felt non-
specifically less well after the drug was started, which often contributed to their 
decision to withdraw. The study population were inevitably deteriorating over time 
due to their terminal cancer and it was difficult to be specific as to whether decline 
was in any way drug related. Participants who withdrew generally felt no better on 
stopping the drug and there were no demonstrable differences between the groups in 
those who withdrew due to concerns over drug side effects after un-blinding. 
 Demographics 
The groups were well matched in all of the variables measured on recruitment to the 
trial other than weight which was significantly higher in the thalidomide group and 
nodal stage. There were significantly more with N0 disease (no lymph nodes 
involved) in the thalidomide group and more with N1 disease (local lymph nodes 
involved) in the placebo group. Tumour stage and metastatic stage were not 
significantly different. 
 
 Thalidomide  Placebo p-value 
Gender 75% 67% 0.58* 
Age (years) 76.3 (8.1) 74.0 (10.6) 0.379** 
Tumour site    
   Ampullary 3% 4%  
   Oesophageal 25% 11%  
   Gastric 19% 44%  
   Small bowel 0% 4%  
   Pancreatic 52% 37%  
Tumour stage    0.70*** 
   0 7% 5%  
   1 17% 0%  
   2 24% 35%  
   3 21% 40%  
   4 31% 20%  
Nodal Stage   0.02*** 
   0 53% 19%  
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   1 47% 76%  
   2 0% 5%  
Metastatic Stage   1.00*** 
…0 47% 43%  
…1 53% 57%  
Functional QOL score 69.4 (16.4) 67.0 (19.0) 0.60** 
Physical functioning 
QOL score 
63.9 (22.0) 59.2 (25.9) 0.45** 
Symptoms QOL score 32.1 (13.7) 34.1 (14.2) 0.58** 
Global health score 48.8 (22.3) 49 (19.5) 0.97** 
Grip strength 25.0 (8.4) 22.5 (9.6) 0.273** 
Weight (kg) 69.0 (14.6) 61.6 (12.9) 0.037** 
Arm muscle area 34.0 (10.7) 29.6(10.0) 0.099** 
DEXA Lean 77.3% (7.3) 75.1% (5.2) 0.29** 
Bioimpedance Lean 71.0% (7.8) 69.0% (7.2) 0.14** 
CRP (mg/l) 42 (40) 42 (41) 0.913*** 
IL-6 (pg/ml) 57 (45.6) 54.6 (50.7) 0.676*** 
Mean (standard deviation)  
* Fisher’s Exact Test 
** T-Test 
*** Mann-Whitney 
Table 3 Baseline characteristics of the study population presented with thalidomide and placebo 
groups separately 
 
One patient described his origin as black. All others described themselves as white 
British 
 Safety and tolerability 
During the trial one patient taking thalidomide developed a deep vein thrombosis and 
one taking placebo had a myocardial infarction. Multiple adverse events were 
reported during the course of the trial. Any reported by the same subject on more than 
one visit were counted once only. Those that pre-dated the trial or had an obvious 
cause other than medication (e.g. dysphagia due to blocked oesophageal stent) were 
discounted and similar symptoms were then grouped into categories by hand without 
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knowledge of the treatment group. The only striking difference was more infections in 
the thalidomide group. Using the Chi squared test the produces a significant 
difference (p=0.04) but we felt a Fischer’s Exact Test to be more appropriate due to 
the low numbers and this suggests a non-significant difference (p=0.071). The larger 
number of participants allocated to thalidomide led to a greater amount of total patient 
time being spent taking active treatment than placebo. The total number of new 
symptoms per patient month was therefore calculated, i.e. total number of symptoms 
divided by total patient trial days per group (placebo 2229, thalidomide 3047) x 28. 
There was no significant difference between groups in the rate of infections per 
patient month. 
 
Symptom reported Frequency 
 Thalidomide Placebo 
Anorexia 12 11 
Constipation 9 5 
Diarrhoea 5 4 
Infections total (p=0.071) 12 3 
    Chest infection    7    1 
    Urinary tract infection    2    0 
    Cholangitis    2    1 
    Cellulitis    0    1 
    Pyrexia unknown origin    1    0 
Fatigue 9 9 
Insomnia 4 4 
Nausea or vomiting 12 5 
Sensory neuropathy 4 3 
Pain (Abdo / head / chest / back) 17 14 
Rash 7 2 
Shortness of Breath 4 2 
Weakness 4 3 
Other (dysphagia, bloating, dizziness etc) 14 10 
Total 113 75 
Total per patient day on trial (113/3047)x28=1.04 (75/2229)x28=0.924 
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Table 4 Showing all symptoms reported during the course of the trial presented with placebo and 
thalidomide groups separately 
 
Of the 10 patients who completed the entire 6 months of the trial, two chose to stay on 
the medication after completion of the trial. 
 Overall clinical results 
There was no significant difference between groups in the change from baseline in 
weight, lean body mass (measured by anthropometry, bio-impedance or by DEXA), 
symptoms or global health score at any time point. At 3 months there was a 
significantly greater deterioration in functional capacity and in grip strength in the 
thalidomide group. Neither change was sustained at 6 months. 
 
 
Graph 1 Showing the difference between groups in change of functional QOL from baseline, 
demonstrating a significantly greater reduction in the thalidomide group at 3 months that is not 
sustained at 6 months (1 month p=0.403; 2 months p=0.194; 3 months p=0.048; 6 months 
p=0.513). 
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Graph 2 Showing the difference between groups in change of grip strength from baseline, 
demonstrating a significantly greater reduction in the thalidomide group at 3 months that is not 
sustained at 6 months (1 month p=0.157; 2 months p=0.086; 3 months 0.005; 6 months 0.0.718). 
 
There was no difference in survival time between groups (thalidomide mean 128.0 
days s.e. 21.0; placebo mean 147.8 days s.e. 27.090). 
 
 
Graph 3 Kaplan Mier survival curve demonstrating no significance difference in survival 
between groups overall (P=0.509) 
 
 82 
 Effect of thalidomide on cytokine levels 
4.5.1 Effect of thalidomide on IL-6 
IL-6 gradually increased over the course of the trial in the placebo group but in the 
thalidomide group it gradually decreased from baseline. 
There was a significant difference between groups in the change in IL-6 level from 
baseline at the 1 month (p=0.021) and 6 month (p=0.01) time-points. 
 
 
Graph 4 Showing the mean IL-6 change from baseline at each time point with thalidomide and 
placebo groups presented separately. Levels in the placebo group gradually increase whereas in 
the thalidomide group IL-6 is reduced from baseline at each time point 
 
In the thalidomide group the baseline level of IL-6 significantly correlated with the 
fall in IL-6 level at 1 month (r=-0.891, p<0.0001) and at 3 months (r=-0.94, p=0.005), 
that is the IL-6 dropped more in those who presented with higher levels. There were 
no correlations in the placebo group. 
4.5.2 Effect of thalidomide on CRP 
Graphs of change in CRP level from baseline also suggest that thalidomide treatment 
may have reversed the natural increase in CRP level as the disease progressed but the 
difference between groups was not significant at any time point 
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Graph 5 Showing the mean CRP change from baseline at each time point with thalidomide and 
placebo groups presented separately. Levels in the placebo group gradually increase whereas in 
the thalidomide group CRP is reduced from baseline at each time point 
 
In the thalidomide group the baseline level of CRP significantly correlated with the 
fall in CRP level at 1 month (r=-0.627, p=0.002) and almost significantly at 3 months 
(r=-0.748, p=0.053). There were no correlations in the placebo group. 
4.5.3 Effect of thalidomide on other cytokines 
Thalidomide treatment did not have a measureable effect on peripheral levels of IL-1, 
IL-1ra, TNF-α, TNFR2 and VEGF levels at any time-point. 
 The significance of baseline IL-6 and CRP levels 
on the clinical response to thalidomide 
The results presented in this section suggest that the likelihood of responding to 
thalidomide treatment may be dependent upon the level of the peripheral 
inflammation at presentation, as evidenced by plasma IL-6 and CRP levels. 
4.6.1 Baseline IL-6 and CRP with survival 
In the placebo group there was a significant negative correlation between both 
baseline IL-6 and baseline CRP with survival (r=-0.655, p<0.001 and r=-0.583, 
p=0.001 respectively). In the thalidomide group this correlation was absent, perhaps 
even reversed (IL-6 r=0.303, p=0.08; CRP r=-0.029, p=0.870). 
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Graph 6 Showing baseline IL-6 levels and survival. In the placebo group higher baseline IL-6 is 
associated with a shorter survival but in the thalidomide group there is a trend in the opposite 
direction 
 
 
Graph 7 Showing baseline CRP levels and survival. In the placebo group higher baseline CRP is 
associated with a shorter survival. This association is absent in the thalidomide group 
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In those participants presenting with IL-6 below the median (</= 44pg/ml), survival 
was significantly (p=0.04) longer in the placebo group than in the thalidomide group 
(mean 232 (SD 142) days vs 123 (SD 133) days) whereas for those participants 
presenting with IL-6 above the median (> 44pg/ml), survival was significantly longer 
in the thalidomide group than the placebo group (p=0.03) (mean 140 (SD 128) days 
vs 58 (SD 66) days). 
 
Graph 8 Kaplan Mier survival curve for those presenting with IL-6≤44pg/ml showing a 
significantly longer survival in the placebo group than the thalidomide group 
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Graph 9 Kaplan Mier survival curve for those presenting with IL-6>44pg/ml showing a 
significantly longer survival in the thalidomide group than the placebo group 
 
4.6.2 Baseline CRP and IL-6 with weight 
In the placebo group there was a significant correlation between baseline CRP (but 
not IL-6) and weight loss from baseline at every time point in the trial. There was no 
correlation between baseline CPR and weight loss in the thalidomide group. There 
was no association seen with IL-6 level in either group. 
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Graph 10 Showing a strong correlation between a higher baseline CRP with increased weight 
loss in the placebo group but no correlation in the thalidomide group. This example is taken at 
visit 3 
 
Weight change from 
baseline 
Month 1 Month 2 Month 3 Month 6 
Placebo 
group 
R -0.570 -0.669 -0.903 -0.927 
Sig (2 
tailed) 
0.013 0.049 0.014 0.023 
Thalidomide 
group 
R -0.159 -0.461 -0.760 -0.932 
Sig (2 
tailed) 
0.458 0.113 0.29 0.068 
All patients R -0.260 -0.371 -0.633 -0.598 
Sig (2 
tailed) 
0.096 0.089 0.015 0.089 
Table 5 Showing a strong and consistent correlation between baseline CRP and weight loss at 
every time point in the placebo group but no association in the thalidomide group 
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4.6.3 Baseline CRP and IL-6 with grip strength and arm 
muscle area 
In the placebo group there was a correlation between a higher baseline CRP and a 
greater reduction of grip strength at 3 months (r= -0.879, p=021) and 6 months (r= -
0.904, p=0.35). There was also a correlation between a higher baseline CRP and 
greater reduction in arm muscle area at 2 months (r= -0.804, p=0.009), 3 months (r= -
0.879, P=0.21) and 6 months (r= -0.894, p=0.41).  
In the placebo group there was also a correlation between a higher baseline IL-6 and a 
greater reduction in both grip strength (r= -0.995, p<0.001) and arm muscle area (r= -
0.937, p=0.19) at 6 months. 
None of these correlations were present in the thalidomide group. 
 
4.6.4 Baseline IL-6 with QOL and functionality 
In those presenting with baseline IL-6 lower than the median (≤44pg/ml), the 
thalidomide group lost less lean body mass as determined by bioimpedance than the 
placebo group (significant at 3 months both in absolute terms (p=0.002), and by 
percentage (p=0.015)). Despite this the thalidomide group showed a non-significant 
trend (p=0.062) towards greater deterioration in physical functioning QOL scores at 1 
month as well as a greater deterioration in functional QOL scores (p=0.059) and a 
trend towards a greater reduction in grip strength (p=0.06) at 3 months.  
 
In those presenting with IL-6 above the median (>44pg/ml), there was a significantly 
greater reduction in grip strength in the thalidomide group than the placebo group at 3 
months (p=0.027) and a tendency to a greater reduction in functional QOL (p=0.075) 
at the same time point despite the improved survival in this group. There was no 
difference in change of LBM between groups. 
 
4.6.5 Summary effects of thalidomide in high and low IL-6 
groups 
The following graphs demonstrate that thalidomide reduced QOL and functionality as 
well as reducing survival time in those with low IL-6 at presentation. In those 
presenting with a high IL-6 it was associated with increased survival time and a 
reduction in weight loss but still caused reduced QOL and functionality. 
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Figure 22 All patients. Showing the difference between groups in the change in a variety of key 
QOL and functionality scores. Every measured outcome deteriorates more in the thalidomide 
than in the placebo group (a higher symptom score indicates a worsening of symptoms) 
 
 
Figure 23 Low IL-6 (<=44pg/ml) patients only. The difference between groups in the change in a 
variety of key QOL and functionality scores. Every measured outcome deteriorates more in the 
thalidomide than in the placebo group (a higher symptom score indicates a worsening of 
symptoms). There is a similar pattern of great deterioration in all measured outcomes in those 
taking thalidomide but the effect is more dramatic in those presenting with a less inflammatory 
picture 
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Figure 24 High baseline IL-6 (>44pg/ml) patients only. The difference between groups in the 
change in a variety of key QOL and functionality scores. Every measured outcome deteriorates 
more in the thalidomide than in the placebo group (a higher symptom score indicates a 
worsening of symptoms). The difference between groups is smaller in this subgroup presenting 
with a more inflammatory picture and there is less weight loss in the thalidomide group than the 
placebo group, overall the group taking thalidomide have a greater deterioration in all other 
measured outcomes 
 
 VEGF 
Baseline VEGF levels were significantly (p=0.39) higher in those with a pancreatic 
than in those with a gastric primary and were significantly increased with more 
advanced tumour stage (p=0.004), metastatic stage (p=0.015) and overall stage 
(p<0.001) (505). There was no difference in VEGF levels between treatment groups 
over time. 
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Graph 11 Showing baseline VEFG levels. Levels are significantly higher in pancreatic cancer 
than in gastric cancer and increased with more advanced tumour stage 
 
There was no other detectable association between any of the other measured 
cytokines (TNF-α, sTNF RII, IL-1b, IL1RA) and measured clinical parameters. 
 
 Validating methods of LBM measurements 
Three methods of measuring body composition (DEXA, bio-impedance and 
anthropometry) were used. DEXA is considered the gold standard. Bio-impedance 
and DEXA are different methods of measuring the same and results should be 
identical. Anthropometry assessed arm muscle area and will therefore produce 
different results but these should be proportionally similar to LBM measured by 
DEXA. 
 
Measurements were taken at five different time points. Data from all time points were 
pooled for a single comparative analysis. 
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All methods of measurement of LBM correlated to a high significance level, both as 
an absolute value (grams) and by percentage. 
 
Correlations 
 Arm muscle 
Area 
Bio LEAN 
(kg) 
DEXA Lean (kg) 
Arm muscle Area 
Pearson Correlation 1 .537** .546** 
Sig. (2-tailed)  .000 .000 
N 152 133 38 
Bio LEAN (kg) 
Pearson Correlation .537** 1 .561** 
Sig. (2-tailed) .000  .001 
N 133 135 33 
DEXA Lean (kg) 
Pearson Correlation .546** .561** 1 
Sig. (2-tailed) .000 .001  
N 38 33 39 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 6 Showing the highly significant correlation between results of all three methods of LBM 
per gram measurement 
 
Correlations 
 Arm muscle 
Area 
Bio LEAN % DEXA Lean % 
Arm muscle Area 
Pearson Correlation 1 -.096 -.599** 
Sig. (2-tailed)  .273 .000 
N 152 133 36 
Bio LEAN % 
Pearson Correlation -.096 1 .622** 
Sig. (2-tailed) .273  .000 
N 133 135 31 
DEXA Lean % 
Pearson Correlation -.599** .622** 1 
Sig. (2-tailed) .000 .000  
N 36 31 37 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 7 Showing the highly significant correlation between results of all three methods of LBM 
as a percentage of total body mass 
 
The paired t-test suggested that bioimpedance measured LBM measurements were on 
average 2kg less than those measured by DEXA (Mean -2.0kg, SD -3.4, -0.5kg, 
p=0.12).  
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Paired Samples Test 
 Paired Differences Sig. (2-tailed) 
Mean 95% Confidence Interval of the 
Difference 
Lower Upper 
 
Bio LEAN - DEXA 
Lean (kg) 
-1.95458 -3.44636 -.46279 .012 
 
Bland Altman plots verify the 2 kg average underestimation of LBM by bio-
impedance. Bland Altman limits of agreement are -9.9kg, 6.0kg. Bio-impedance 
tended to over-estimate LBM in those with high LBM and underestimate LBM in 
those with less LBM as measured by DEXA. 
 
Figure 25 Bland Altman plot comparing DEXA and bio-impedance 
 
 
The mean difference between arm muscle area and DEXA was 18.5. This in itself is 
of little relevance, the two measures are not the same and were not expected to 
produce identical or even similar results. The wide range in the standard deviation 
(S.D. 1.4, 35.5) is more concerning with anthropometry tending to overwstimate more 
as the DEXA measured LBM increases. 
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Figure 26 Bland Altman plot comparing DEXA and arm muscle area 
 
 
Comparing anthropometry with bio-impedance produces similar results to comparing 
it with DEXA. The mean difference is 14.4 with standard deviation -4.1-32.8. 
 
Figure 27 Bland Altman plot comparing bioimpedance and arm muscle area 
 
 
ICC values between 0.7 are generally taken to indicate reasonable agreement. Values 
above 0.8 are considered good and those above 0.9 are considered excellent. The 
values presented below (Table 8) suggest an excellent (but not perfect) agreement 
between the values obtained for measurement of LBM by bioimpedance and by 
DEXA. Anthropometry in our hands showed a statistically reasonable agreement with 
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LBM measured by both DEXA and by bioimpedance but we felt not to a clinically 
acceptable level in the context of this trial. 
 
Table 8 ICC values for LBM measurement methods 
ICC 
value 
Bioimpedance (kg) 
vs DEXA (kg) 
Anthropometry 
(cm2) vs DEXA (kg) 
Bioimpedance (kg) vs 
anthropometry (cm2) 
Single 
measures 
0.92 (0.84, 9.61) 0.59 (0.33,0.77) 0.53 (4.0, 6.5) 
Average 
measures 
0.96 (0.92, 0.98) 0.74 (0.49, 0.87) 0.70 (0.57, 0.78) 
ICC value (95% confidence interval) 
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Chapter 5 Discussion 
 Overall 
We found thalidomide to be better tolerated than in a recently published study by 
Wilkes(506). This may have been because we suggested patients should increase the 
dose gradually as tolerance allowed rather than starting immediately at 200mg, 
although there was no measureable relationship of side effects to drug dose. The 
terminally ill patients in the trial often had multiple symptoms and it was inevitably a 
matter of judgement which were expected as part of their disease process and which 
could be a side effect of the drug. We therefore grouped relatively minor symptoms 
into categories to assess whether one group was experiencing a greater number than 
the other. The only possible difference was an increase in reported infections in the 
thalidomide group, not an expected finding. The difference in absolute number of 
infections between groups was significant using the Chi Squared test (p=0.04) but 
non-significant when analysed using the more appropriate Fischer’s Exact Test 
(p=0.071) and it is likely that this was a chance finding. When time spent on the 
medication was taken into account, there was no difference in infections between 
groups. The overall number of new reported symptoms per patient per trial month 
were remarkably similar between groups – 0.924 in the placebo group and 1.04 in the 
thalidomide group. Of the 10 patients who completed the trial (4 active, 6 placebo) 
only two (both active) chose to stay on the study medication. These decisions will 
have been influenced by our counsel though and we generally advised people that the 
known long-term side effects may well outweigh any unknown but potential long-
term benefits. 
 
Thalidomide had little if any effect on survival, QOL or cachexia overall. All non-
significant trends were suggestive of thalidomide conferring harm rather than benefit. 
For those patients with a low inflammatory burden at presentation thalidomide 
reduced survival, and increased the deterioration in QOL. For those presenting with a 
high IL-6 the effects were more mixed. In this group thalidomide treatment was 
associated with increased survival and a reduction in weight loss. Disappointingly this 
did not translate into clinical benefit. The reduction in weight loss was not echoed by 
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a reduction in LBM loss and QOL was worse in the thalidomide group, although to a 
lesser extent than it was in the patients with a lower inflammatory burden. We 
hypothesise that the anti-inflammatory effect of the drug had some benefit in those 
who had inflammation to treat but that the know side effect of somnolence reduced 
activity levels across the board leading to reduced QOL. Those without an 
inflammatory burden did badly in every measured outcome with thalidomide as they 
had nothing to gain from the anti-inflammatory effects of the drug. Although the 
improved survival and reductions in weight loss in the thalidomide treated group with 
high inflammatory burden are interesting from a scientific perspective, in reality few 
people with incurable cancer would feel that gains in survival are worth a decrease of 
QOL in the time they have remaining. 
 
Thalidomide inhibits production of TNF-α but has no influence on IL-6 production 
from monocytes stimulated with lipopolysaccharide in vitro(449). Our study showed a 
significant reduction in IL-6 serum levels by 4 weeks after thalidomide treatment but 
no change in peripheral TNF-α levels. This could be a direct in vivo effect or could be 
the final result of a complex cytokine cascade. Equally, mononuclear cells taken from 
the blood of people with pancreatic cancer have been shown to produce larger 
amounts of TNF-α if taken from a patient with an acute phase response (as evidenced 
by elevated CRP)(227). Perhaps, by reducing this acute phase response, thalidomide 
is dampening down TNF-α production at a local level, not detectable in the serum. 
 
High CRP and IL-6 levels have previously been associated with a variety of negative 
outcomes in a variety of circumstances (507;508) including degree of cachexia(509) 
and shortened survival in pancreatic cancer patients(510). In our placebo group, 
higher CRP and IL-6 levels were associated with reduced survival, greater loss of grip 
strength, weight and arm muscle area. In our thalidomide group these correlations 
were not present suggesting a possible protective effect for those patients with a high 
inflammatory burden who would otherwise be expected to have a poor prognosis. IL-
6 is also known to be a potent tumour growth factor (511-513), so it is possible that by 
reducing IL-6 levels the thalidomide produced benefits through an anti-tumour action 
instead or as well as an anti-cachexia action. It seems less likely that this would have 
had a large influence as the survival times for most patients on this trial are were 
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probably too short to allow a substantial benefit and previous murine trials of anti-IL-
6 antibodies have been unsuccessful in slowing tumour growth(190) 
 
The median baseline IL-6 of 44.1pg/ml was identified as a cut off, under which 
survival seemed to be shortened in those taking thalidomide but above which it 
seemed to be lengthened. In this trial, those who seemed to benefit from thalidomide 
were not therefore those with a more obviously cachexic picture (as evidenced by 
recent weight loss or reduced strength, lean body mass or quality of life at 
presentation) but those with higher inflammatory cytokines. Perhaps the benefits of 
thalidomide in cachexia suggested by previous trials (514-517), have been mediated 
by a reduction of the inflammatory drivers of this condition. Cachexia is a complex, 
multi-factorial condition only partly driven by inflammation. If there is not a large 
inflammatory component to an individual’s cancer related weight loss there may be 
nothing to gain, or even something to lose, from taking an anti-inflammatory drug 
with potentially harmful side effects.  
 
 Validating methods of LBM measurements 
Anthropometry, bio-impedance and DEXA scanning were used with DEXA being 
considered the gold standard but not available for each trial visit. Results were highly 
correlated for all methods (p≤0.001). Bioimpedance overestimated the LBM 
measurement by an average of 2kg. ICC values suggested excellent, although not 
perfect, agreement between bioimpedance and DEXA which we felt was clinically 
acceptable. ICC values comparing anthropometry with DEXA (or with bioimpedance) 
were only just reasonable. Bland-Altman limits of agreement comparing 
bioimpedance to DEXA were not narrow, suggesting that the two methods are not 
interchangeable. Bioimpedance was therefore taken as the primary method of LBM 
measurement for the purposes of the trial. 
 
Bioimpedance works on the principle that impedance of current flow through the 
body is dependent on internal structures such as cell membranes and different tissues. 
Different current frequencies will be impeded differently so by applying impedance at 
varying mHz and comparing results, equations can be developed to provide an 
estimate of body composition and cell membrane permeability, Bodystat®’s ‘Illness 
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Marker’(518). Equations developed on the results for healthy volunteers with not be 
directly transferable to an unwell population and no specific equations have yet been 
developed in terminal cancer patients. Previous investigators have also found 
bioimpedance to be an imperfect measure of LBM in this patient population (519). 
Accuracy of bioimpedance measurements can be improved by taking the reading prior 
to food consumption(520) but we felt it would be unethical to in any way restrict food 
intake in our patient group so did not take this into account. Equations specific to this 
group are under development and will increase accuracy in the future (see 5.5). 
 Recruitment difficulties 
The overwhelming difficulty in running this trial was slow recruitment. It is well 
documented that there are particular challenges in recruiting to palliative care trials 
including the nature of the patient population, the high prevalence of cognitive 
problems and the unstable nature of the disease process(521;522). Gatekeeping, that is 
clinical staff preventing access to potential candidates, is also a well known 
problem(523). Many medical staff consider it unethical to include palliative patients 
in clinical trials(524). It is difficult to exactly quantify the influence of these factors 
on our difficulties but we certainly found that, despite using a number of methods to 
locate eligible patients, the number we were able to find was far less than that our 
predictions suggested. A number of patients mentioned during the consent process 
that although their consultant had suggested they consider the trial, some members of 
the nursing staff had advised them against it, presumably in an understandable attempt 
to protect their patient from unnecessary interference. There were times during the 
trial when the front line investigators felt uncomfortable, usually when taking clinical 
measurements from people who very obviously had a short time to live and would 
generally be having any unnecessary tests or treatments withdrawn. A bigger problem 
was the introduction of gemcitabine. The trial was conceived at a time when a large 
number of people with a new diagnosis of upper gastrointestinal adenocarcinoma had 
no real palliative options available. The beginning of the trial coincided with the 
introduction of gemcitabine as a palliative chemotherapy. The population of potential 
participants therefore reduced but it also changed the dynamic of the recruitment 
process. During our previous trial people diagnosed with inoperable pancreatic cancer 
had no other treatment options and were often given information on the trial at initial 
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diagnosis. The introduction of gemcitabine meant there were other options available. 
This meant that only those who were very sure they did not want to consider this 
could be recruited immediately and by their nature people refusing palliative 
chemotherapy are also likely to refuse a clinical trial. Most people went into the 
multidisciplinary team (MDT) meeting process whereby their treatment options are 
discussed at a weekly meeting. After that meeting, if gemcitabine was felt appropriate 
they would require a pancreatic biopsy for histological proof of the diagnosis, usually 
taking 1-3 weeks for the procedure to be completed and results to be available. 
Gemcitabine could then be started. A number of people would then stop the 
gemcitabine due to side effects and become eligible for our trial. However, by that 
time their already short prognosis would be substantially shorter and often they would 
have deteriorated significantly or died; often they would have simply had had enough 
of medical interventions and be unwilling to even consider the trial and by that stage 
they will have made a definite decision to stop all active interventions, meaning that 
they wouldn’t have any need for further medical outpatient appointments and so 
become inaccessible. It is noticeable that another group running a similar trial using 
thalidomide in terminal oesophageal cancer(525) at around the same time were having 
similar recruitment difficulties(526). 
 
The trial recruited slower than predicted and there were a number of repercussions, 
mainly that we planned to recruit 180 patients but pragmatically stopped at 63 rather 
than allow it to continue with slow progress.  
 
During the trial, the British drug company that agreed to supply our trial medications 
was bought out by another much larger American company. Although contracts were 
honoured, communication was much more difficult with the new company and 
mistakes were made when replenishing drug, namely that blocks of four should have 
been re-supplied until all trial numbers in that block were used but in the event new 
blocks of four were supplied. This wouldn’t have caused a problem if the trial had 
fully recruited as blocks would subsequently been filled but because it was stopped 
early caused an unequal allocation of patients to active and placebo groups. Had we 
been able to recruit faster, the trial would have been complete before the takeover and 
this would have been avoided.  
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Thanks to support from the Moulton Charitable Trust and the National Cancer 
Research Network (NCRN), there was a generous amount of investigator and research 
nurse time available for the trial but only for a limited period of time. The drawn out 
recruitment process meant that the PI had to return to part-time clinical work and the 
research nurses had to dedicate more of their time to other trials. This probably 
resulted in potential recruits being missed. 
 
The lower number of participants recruited led to an underpowered trial. Trials 
stopped early due to interim analyses showing overt efficacy are prone to over-
estimation of beneficial effect(527). As this trial was stopped early simply due to slow 
recruitment it is unlikely that positive findings are over estimated but negative 
findings may be false. 
 Funding 
This trial was funded by a generous research grant from the Moulton Charitable Trust 
(registered charity number 1109891). The National Cancer Research Network 
supported the time of the research nurses. Thalidomide and placebo were supplied 
free of charge from Pharmion Plc. 
 Future directions 
Bodystat® are currently using our data to develop software equations to provide more 
accurate LBM measurements in this patient population.  
 
Further clinical trials using thalidomide in this patient population are unlikely to be 
conducted, partly because the marketing strategy of the drug company is towards 
Lenalidomide, a newer thalidomide analogue with a more favourable side effect 
profile, and towards haematological disease, meaning that they would be reluctant to 
supply thalidomide as a trial medication for this purpose. Our results suggest that 
those patients with a high inflammatory burden benefit from anti-inflammatory 
intervention and that a medication with a wide range of anti-inflammatory effects has 
a benefit not previously delineated in treatments with more specific influences. This 
lends support to the recent tendency to use a combination of therapies to control 
cancer cachexia. 
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Future trials in cancer cachexia should measure inflammatory cytokines when 
possible and clarify whether this effect is reproducible. If so it may be possible in the 
future to predict those patients likely to benefit from the wide range of anti-
inflammatory therapies available. 
 
Any future trials need to be carefully planned with particular thought given to likely 
extreme recruitment difficulties in this patient population and the ethical dilemmas 
involved in running any sort of clinical trial with participants at the very end of their 
lives. 
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Chapter 6 Conclusions 
In incurable upper gastrointestinal cancer patients, presenting with an acute 
inflammatory response predicts a poor prognosis in terms of survival, functional 
quality of life, grip strength and symptomatology. 
 
Thalidomide treatment of this population leads to a reduction in serum IL-6 levels, 
particularly marked in those presenting with high IL-6 levels at baseline. Overall 
thalidomide does not affect survival but leads to a significant deterioration in 
functional quality of life, grip strength and an increase in negative symptoms. 
 
Thalidomide treatment in those presenting with a low inflammatory burden is 
associated with worse outcomes for survival, weight loss and QOL. In those with a 
high inflammatory burden it is associated with a survival advantage and a reduction in 
weight loss but still a reduction in QOL which to most patients with terminal cancer is 
their primary concern. 
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Chapter 8 Appendices 
 Establishing the IL-6 ELISA SOP 
8.1.1 Il-6 Checkerboard 11.10.2006 
Manufacturers suggested ranges: 
Capture antibody: 2-8μg 
Detection antibody 100-400ng 
 
These suggested ranges assume use of a 96 well plate. We found we often required 
different doses for the 384 well plate. The following checkerboard was set up to 
ascertain the optimal antibody pair using 2 or 4μg of capture antibody and between 
16-1000ng of detection antibody. 
 
Figure 28 Layout for IL-6 checkerboard 11.10.2006 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Detection 
A                         1000ng/ml 
B                         500ng/ml 
C                         250ng/ml 
D                         125ng/ml 
E                         62.5ng/ml 
F                         31.25ng/ml 
G                         16ng/ml 
H                         0 
I                         0 
J                         16ng/ml 
K                         31.25ng/ml 
L                         62.5ng/ml 
M                         125ng/ml 
N                         250ng/ml 
O                         500ng/ml 
P                         1000ng/ml 
 4ug/ml 2ug/ml 4ug/ml 2ug/ml Capture concentration  
 
100pg/ml 
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50pg/ml 
10pg/ml 
0pg/ml 
 
All standards in pure undiluted plasma 
 
 
 
Table 9 IL-6 checkerboard results 
 
 
Table 10 IL-6 checkerboard with relevant background subtracted 
 
standard concentration pg/ml: 100 50
All samples in my pure undiluted plasma 10 0
RLU/s 1 2 3 4 5 6 7 8 9 10 11 12
A 100% 1000 953780 1000780 955918 555266 704869 681228 446806 457974 429416 313565 328100 278126
B 50% 500 956665 974490 883084 558488 619479 609549 409012 431814 418417 277220 295182 248982
C 25% 250 866072 917136 848880 434973 628191 552558 339084 383969 396114 256130 269024 237450
D 12.50% 125 784290 830970 787925 392971 589083 550378 331392 367785 370620 244432 251842 222642
E 6.25% 63 678099 784769 763078 409523 537802 534337 300651 343601 333861 228530 208196 165607
F 3.13% 31 558515 705004 658536 395604 475012 471889 261416 313506 267380 183415 161966 126058
G 1.56% 16 2303 2206 1717 1113 1418 1840 1351 1390 998 1123 1330 1641
H 0.00% 0 1950 1350 1166 768 893 1103 960 948 841 891 982 1218
I 100% 1000 124479 128888 120770 70667 85850 82143 27083 32759 26134 20483 19196 16532
J 50% 500 96120 91831 90769 46273 53970 58247 8585 9938 7625 5568 7076 6041
K 25% 250 82758 80399 76075 38300 46797 48799 4678 6077 4588 3130 3178 3609
L 12.50% 125 66205 74228 73540 40521 51276 45037 4039 5268 2817 2216 2101 3382
M 6.25% 63 64254 67148 67452 36792 42510 39409 2486 2928 2103 1672 1395 2118
N 3.13% 31 55922 56154 51984 30762 34536 32924 1564 2256 1650 1500 1465 1998
O 1.56% 16 1557 1593 1038 1097 1218 986 837 1117 1003 870 1194 2453
P 0.00% 0 1968 1713 1039 1019 1235 1036 794 1138 1030 952 1250 2474
averages average st error % error average st error % error average st error % error average st error % error
100% 1000 970159.3333 18766.48184 1.934371107 647121 56867.08182 8.78770459 444732 10176.34384 2.288196901 306597 18176.42618 5.928442279
50% 500 938079.6667 34262.40775 3.652398509 595838.6667 23140.39164 3.88366733 419747.6667 8102.80218 1.930398385 273794.6667 16468.29805 6.014835223
25% 250 877362.6667 25103.08496 2.861198216 538574 68847.52382 12.78329883 373055.6667 21241.83206 5.694011365 254201.3333 11225.39944 4.415948294
12.50% 125 801061.6667 18360.07364 2.291967573 510810.6667 73447.80302 14.37867449 356599 15468.58014 4.337808053 239638.6667 10732.94073 4.478801721
6.25% 63 741982 39864.79109 5.37274369 493887.3333 51676.91511 10.46330036 326037.6667 15922.92425 4.883768312 200777.6667 22705.72322 11.30888888
3.13% 31 640685 52932.74238 8.261898183 447501.6667 31799.87529 7.106090916 280767.3333 20158.83857 7.179908836 157146.3333 20492.41631 13.04034009
1.56% 16 2075.333333 222.0972009 10.70176041 1457 258.1404656 17.71725914 1246.333333 152.6963217 12.25164389 1364.666667 184.3669349 13.51003431
0.00% 0 1488.666667 289.9011326 19.47387814 921.3333333 119.7044973 12.99252865 916.3333333 46.32673814 5.055664402 1030.333333 119.3405491 11.58271263
100% 1000 124712.3333 2873.700953 2.304263641 79553.33333 5597.349924 7.035971579 28658.66667 2533.248935 8.839381694 18737 1424.88789 7.604674656
50% 500 92906.66667 2003.259136 2.156206016 52830 4290.621692 8.121562922 8716 821.6942862 9.427424119 6228.333333 545.3605841 8.756123908
25% 250 79744 2396.600822 3.005368206 44632 3941.615722 8.831367006 5114.333333 590.3686701 11.543414 3305.666667 186.5265843 5.642631371
12.50% 125 71324.33333 3144.361329 4.408539389 45611.33333 3818.697444 8.372255676 4041.333333 866.5605384 21.44244156 2566.333333 501.1438583 19.52762144
6.25% 63 66284.66667 1248.160513 1.883030535 39570.33333 2024.03092 5.115021153 2505.666667 291.9300715 11.65079439 1728.333333 257.9363617 14.92399392
3.13% 31 54686.66667 1657.069904 3.030116855 32740.66667 1339.025267 4.089792309 1823.333333 266.6920821 14.62662242 1654.333333 210.8154801 12.7432287
1.56% 16 1396 219.5984973 15.73055138 1100.333333 82.04978164 7.456811418 985.6666667 99.56237576 10.10101885 1505.666667 591.3223881 39.27312739
0.00% 0 1573.333333 339.4041347 21.5722967 1096.666667 84.92447625 7.743873214 987.3333333 124.3972133 12.59931262 1558.666667 570.3408338 36.59158472
detection antibody capture antibody 4ug/ml
capture antibody 4ug/ml
capture antibody 2ug/ml capture antibody 4ug/ml
capture antibody 2ug/ml capture antibody 4ug/ml capture antibody 2ug/ml
capture antibody 2ug/ml
4 ug/ml 2 ug/ml 4 ug/ml 2 ug/ml
100% 1000 941500.6667 628384 416073.3333 287860
50% 500 929363.6667 589610.3333 411031.6667 267566.3333
25% 250 872248.3333 535268.3333 367941.3333 250895.6667
12.50% 125 797020.3333 508244.3333 352557.6667 237072.3333
6.25% 63 739476.3333 492159 323532 199049.3333
3.13% 31 638861.6667 445847.3333 278944 155492
1.56% 16 1089.666667 -48.66666667 260.6666667 -141
0.00% 0 501.3333333 -637.3333333 -71 -528.3333333
100% 1000 96053.66667 60816.33333
50% 500 84190.66667 46601.66667
25% 250 74629.66667 41326.33333
12.50% 125 67283 43045
6.25% 63 63779 37842
3.13% 31 52863.33333 31086.33333
1.56% 16 410.3333333 -405.3333333
0.00% 0 586 -462
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Table 11 IL-6 checkerboard signal : noise ratio 
 
 
Figure 29 RLUs emitted by detection antibody concentration, standard concentration 100pg/ml 
 
 
100% 1000 4 ug/ml 2 ug/ml 4 ug/ml 2 ug/ml
50% 500 33.85221457 34.5370657 15.51823765 16.36318514
25% 250 107.6273138 95.6658282 48.15829127 43.95953974
12.50% 125 171.5497621 162.9244731 72.94316626 76.89865887
6.25% 63 198.2171726 199.0429926 88.23795777 93.37784128
3.13% 31 296.1215911 285.7593057 130.1201277 116.1683703
1.56% 16 351.38117 270.5027201 153.9857404 94.99073141
0.00% 0 2.105512344 0.967677662 1.26445722 0.906353775
100% 1000 1.507765024 0.591103507 0.928089129 0.661035073
50% 500 4.351644645 4.245788191
25% 250 10.65932385 8.482204977
12.50% 125 15.59225706 13.50166381
6.25% 63 17.6487133 17.77295753
3.13% 31 26.45390448 22.89508197
1.56% 16 29.99268739 19.79085231
0.00% 0 1.416300304 0.730794775
1.593517893 0.703592814
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Figure 30 RLUs emitted by detection antibody concentration, standard concentration 50pg/ml 
 
 
Figure 31 RLUs emitted by detection antibody concentration, standard concentration 10pg/ml 
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Figure 32 RLUs emitted by detection antibody concentration, standard concentration 0pg/ml 
 
 
Figure 33 RLUs emitted with relevant background level subtracted by detection antibody 
concentration, standard concentration 100pg/ml 
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Figure 34 RLUs emitted with relevant background level subtracted by detection antibody 
concentration, standard concentration 50pg/ml 
 
 
Figure 35 RLUs emitted with relevant background level subtracted by detection antibody 
concentration, standard concentration 10pg/ml 
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Figure 36 Il-6 signal : noise ratio by detection antibody concentration, standard concentration 
100pg/ml 
 
 
Figure 37 Il-6 signal : noise ratio by detection antibody concentration, standard concentration 
50pg/ml 
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Figure 38 Il-6 signal : noise ratio by detection antibody concentration, standard concentration 
10pg/ml 
 
 
Interpretation: 
An increase in the capture antibody from 2 to 4μg results in an increase in RLUs 
emitted at all levels of standard tested with no real increase in the background (noise) 
level. Signal : noise ratios therefore favoured using 4μg. As the concentration of 
detection antibody increased the absolute level of RLUs increased slightly for each 
level of standard concentration. Background (noise) levels increased proportionally 
more though resulting in a more favourable ratio at lower detection levels  
 
All subsequent ELISAs for IL-6 used 4µg/ml capture antibody and 50ng/ml detection 
antibody. 
 ELISA to establish the optimum serum dilution for 
IL-6 detection 
Capture 4μg/ml throughout 
Detection 50ng/ml throughout 
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Serum was spiked with concentrations of recombinant standard at low levels to 
establish the optimum dilution at the lower end of the range. After spiking serum was 
serially diluted with standard buffer. 
 
Figure 39 IL-6 serum dilutions. Pure serum 
 
 
Figure 40 IL-6 serum dilutions. 50% serum, 50% standard buffer 
 
Standard curve IL-6 Date 12.10.06 100% serum
standard concentration [pg/ml] 25 12.5 6.25 3.125 1.5625 0 0 Background
10584 6716 4868 4270 3750 3747 3203 3747 2454
8640 5169 3884 2922 2849 2454 2709 3203 2709
8105 4110 3238 2532 2267 1777 2435 1777 2435
Average reading 9109.6667 5331.6667 3996.6667 3241.3333 2955.3333 2659.3333 2782.3333 Average 2720.833
standard deviation 1304.5307 1310.5931 820.81992 911.94371 747.19632 1000.9227 389.21631 St dev 623.07903
coefficient of variation 14.32% 24.58% 20.54% 28.13% 25.28% 37.64% 13.99% CV 22.90%
Average - average background 6388.8333 2610.8333 1275.8333 520.5 234.5 -61.5 61.5
detection level 4590.0704 4590.0704 4590.0704 4590.0704 4590.0704 4590.0704 4590.0704
(average background + 3 SD)
IL-6
7.691521
22.90%
28.13%
Serum dilution
max signal CV
detection level
background CV
y = 243.03x + 2720.8
R² = 0.9868
0
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Standard curve IL-6 Date 12.10.06 50% serum, 50% PBS
standard concentration [pg/ml] 50 25 12.5 6.25 3.125 1.5625 0 0 Background
23645 10194 5818 4264 3951 3993 3116 3144 3116 3144
23220 11243 5687 3863 3233 2706 2425 2150 2425 2150
21070 9023 5522 3513 3393 2299 2169 1879 2169 1879
Average reading 22645 10153.333 5675.6667 3880 3525.6667 2999.3333 2570 2391 Average 2480.5
standard deviation 1380.4438 1110.5586 148.32509 375.7885 376.93678 884.27503 489.86835 666.04579 St dev 485.6675
coefficient of variation 6.10% 10.94% 2.61% 9.69% 10.69% 29.48% 19.06% 27.86% CV 19.58%
Average - average background 20164.5 7672.8333 3195.1667 1399.5 1045.1667 518.83333 89.5 -89.5
detection level 3937.5025 3937.5025 3937.5025 3937.5025 3937.5025 3937.5025 3937.5025 3937.5025
(average background + 3 SD)
IL-6
3.875728
7.751456
19.58%
29.48%
Plasma dilution
max signal CV
detection level
background CV
adjusted detection
y = 375.93x + 2480.5
R² = 0.9759
0
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10000
15000
20000
25000
0 10 20 30 40 50 60
lu
m
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e
s
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e
n
c
e
standard concentration (pg/ml)
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Figure 41 IL-6 serum dilutions. 25% serum, 75% standard buffer 
 
 
Figure 42 IL-6 serum dilutions. 100% standard buffer 
 
 
Interpretation: 
This run was disappointing in that CVs of both signal and background were 
unacceptably high and absolute values were lower than on other runs. Perhaps the 
Standard curve IL-6 Date 12.10.06 25% serum, 75% PBS
standard concentration [pg/ml] 25 12.5 6.25 3.125 1.5625 0 0 Background
9066 4630 3085 2756 2482 1977 1988 1977 1988
8363 4406 3483 2599 2125 2075 2065 2075 2065
8425 5235 3263 2909 2886 2241 2255 2241 2255
Average reading 8618 4757 3277 2754.6667 2497.6667 2097.6667 2102.6667 Average 2100.167
standard deviation 389.21588 428.84379 199.369 155.0043 380.74182 133.45161 137.42756 St dev 110.62612
coefficient of variation 4.52% 9.02% 6.08% 5.63% 15.24% 6.36% 6.54% CV 5.27%
Average - average background 6517.8333 2656.8333 1176.8333 654.5 397.5 -2.5 2.5
detection level 2432.045 2432.045 2432.045 2432.045 2432.045 2432.045 2432.045
(average background + 3 SD)
IL-6
1.339922
5.359687
5.27%
15.24%
Serum dilution
max signal CV
detection level
background CV
adjusted detection
y = 247.66x + 2100.2
R² = 0.9863
0
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Standard curve IL-6 Date 12.10.06 100% PBS
standard concentration [pg/ml] 50 25 12.5 6.25 3.125 1.5625 0 0 Background
30250 14932 12613 8050 7647 7204 5019 4325 5019 4325
32383 12623 11926 8170 6804 5891 4826 3455 4826 3455
29863 15970 11508 7448 7744 5945 3200 5945 3200
Average reading 30832 14508.333 12015.667 7889.3333 7225.5 6946.3333 5263.3333 3660 Average 4461.667
standard deviation 1357.0715 1713.2491 557.9304 386.88672 596.09102 952.99335 598.17584 589.85168 St dev 936.97166
coefficient of variation 4.40% 11.81% 4.64% 4.90% 8.25% 13.72% 11.36% 16.12% CV 21.00%
Average - average background 26370.333 10046.667 7554 3427.6667 2763.8333 2484.6667 801.66667 -801.66667
detection level 7272.5816 7272.5816 7272.5816 7272.5816 7272.5816 7272.5816 7272.5816 7272.5816
(average background + 3 SD)
IL-6
5.516508
21.00%
13.72%
Serum dilution
max signal CV
detection level
background CV
y = 509.54x + 4461.7
R² = 0.9719
0
5000
10000
15000
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standard was inadvertently diluted by a factor of 10. It does demonstrate though that 
there is no obvious advantage in diluting the serum as detection levels and CVs 
remained similar. 
 Final SOP ELISA - Trial run, healthy volunteers 
After a few days of refining the technique, an SOP was established producing low 
signal and background CVs and low detection levels which was successful in 
analysing both spiked serum and raw serum from healthy human volunteers 
 
 
 
 Final IL-6 ELISA SOP 
Luminescence immunoassay 384 well plate 
Reagents 
Matched pair antibodies (capture and detection) (R&D) 
Recombinant standard protein (R&D) 
Lab peoples blood IL-6 Date 16.10.06 100% Serum Detection 50ng/ml
Standard curve
standard concentration [pg/ml] 50 25 12.5 6.25 3.125 1.5625 0 0 Background
195504 69050 33782 29904 13503 6311 2001 1935 2001 1935
189199 65372 42626 21861 11827 5954 1679 1723 1679 1723
Average reading 192351.5 67211 38204 25882.5 12665 6132.5 1840 1829 Average 1834.5
standard deviation 4458.3083 2600.7387 6253.6524 5687.2598 1185.111 252.43712 227.68838 149.90664 St dev 136.41389
coefficient of variation 2.32% 3.87% 16.37% 21.97% 9.36% 4.12% 12.37% 8.20% CV 7.44%
Average - average background 190517 65376.5 36369.5 24048 10830.5 4298 5.5 -5.5
detection level 2243.7417 2243.7417 2243.7417 2243.7417 2243.7417 2243.7417 2243.7417 2243.7417
(average background + 3 SD)
IL-6
1.763134
7.44%
9.82%
21.97%
Calculated IL-6 levels Standard
deviation
Subject 1 23762 23606 23362
23546 24842 21534
Subject 2 3359 3300 2771
3098 3485 2944
Subject 3 40574 44220 47717
41871 44054 51091
Subject 4 14779 17257 15310
average signal CV
Serum dilution
max signal CV
detection level
background CV
15782
23442
8.57%
8.64%
8.27%1304.6873
4.57%
Average RLU
1072.0985
270.79346
3881.4563
3159.5
44921.16667
5.454748725
Calculated IL-6 pg/ml
x=(y+4222.2)/3667.3
CV
7.543478854
2.012843236
13.40042175
y = 3667.3x - 4222.2
R² = 0.9736
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Horse peroxidase reagent (HPR) (Sigma) 
Luminol: Supersignal West Pico Chemiluminescence Substrate (Pierce) 
Sodium azide (NaN3) comes as powder – 100%. Standardly make up to 8% in fridge 
(8g in 100ml PBS) 
Tween 20 solution 10% (Sigma) 
Bovine serum albumin (BSA) (7.5% Sigma) 
  
Buffers 
Capture buffer:  
Need 14ml: (0.03ml per well x 384 wells = 11.52ml + allow extra for wastage) 
PBS +/- 0.08% NaN3, filtered + 0.05% Tween  
14ml PBS + 0.14ml 0.8% NaN3 + 70μl 10% Tween 
Blocking buffer:  
Need 60ml: (0.127ml per well x 384 wells = 48.77ml + allow extra for wastage) 
PBS + 1% BSA (7.5%) + 3% lactose + 0.08% NaN3  
51.5ml PBS + 8ml 7.5% BSA + 1.8g lactose (measure on fine scales) + 0.6ml 8% 
NaN3 
Standard buffer: 
Need 14ml: (0.03ml per well x 384 wells = 11.52ml + allow extra for wastage) 
PBS + 1% BSA + 0.05% Tween + 0.08% NaN3, filtered 
9.43ml PBS + 1.87ml 7.5% BSA + 70μl 10% Tween + 140μl NaN3 
Detection buffer:  
Need 14ml: (0.03ml per well x 384 wells = 11.52ml + allow extra for wastage) 
PBS + 1% BSA + 0.05% Tween + 0.08% NaN3 
9.43ml PBS + 1.87ml 7.5% BSA + 70μl 10% Tween + 140μl NaN3 
HPR buffer:  
Need 14ml: (0.03ml per well x 384 wells = 11.52ml + allow extra for wastage) 
PBS + 0.05% Tween 
14ml PBS + 70μl 10% Tween 
Wash buffer: 
Pre-detection 
PBS + 0.05% Tween + 0.08% NaN3, filtered 
1l PBS + 5ml 10% Tween + 10ml 8% NaN3 
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Post-detection 
PBS + 0.05% Tween no NaN3 
1l PBS + 5ml 10% Tween no NaN3 
 
Requirements 
Plasma dilution: None  
Capture 4ug/ml 
Standard start from about 1000pg/ml 
Detection 50ng/ml  
 
Calculations 
Concentration needed  x volume needed = stock volume 
Stock concentration     
 
Capture 
Capture stock = 500μg/ml 
Need 14ml of 4μg/ml 
 
4    x 14 = 0.112ml (112μl) capture stock in 14ml capture buffer 
500 
 
Standard 
Standard stock = 10μg/ml (10,000,000pg/ml) 
Start at 800pg/ml (even the first row gets diluted 50:50) 
Need 90μl (30μl per well x 3 wells = 90μl) of 800pg/ml 
 
Tiny amounts – too small to accurately pipette therefore: 
Dilute standard stock 10μl into 10ml standard buffer to produce 10,000pg/ml solution 
Then: 
 
800 x 10 = 0.8ml of diluted standard stock in 10ml standard buffer 
10,000 
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Detection 
Detection stock = 200μg/ml (200ng/μl).  
Need 14ml (0.03ml per well x 384 wells = 11.52ml – allow extra for wastage) of 
50ng/ml 
 
50 x 14 = 3.5μl detection stock in 14ml detection buffer 
200 
 
Method 
Prior to incubating at each step remove the vial required for the next stage from the 
freezer. When defrosted, Vortex the solution and prepare during the incubation time 
for the next step 
 
Microplate 
1. Label the 384 Nunc maxisorp plate (340372) with tested antigen date and 
draw lines dividing it into subsets of 3 wells each, leaving the final 3 cells of 
the last 13 rows free for control samples 
2. Set up a template on Microsoft office Word mapping the 384 with location of 
each patient sample and control run 
Capture 
3. Use 4ug/ml capture  
4. Use a multi-channel pipette (green top) to put 30ul into each cell. Try to get 
the tip of the pipette to the bottom of each well to avoid precipitation on the 
sides 
5. Cover the plate with plastic sticky foil to avoid evaporation, put the lid on and 
wrap in and plastic bag 
6. Leave overnight at 4°c 
7. Put 1 litre sterile water with 5 tablets PBS onto stirrer for 20mins 
8. Add 5ml Tween and 10ml 8% NaN3 
9. Set up the plate washer using wash buffer 
a. Wash joins to fill nozzle on washer 
b. Vac on pump joins to top bung on waste bottle 
c. Side port on waste bottle connects to vac nozzle on pump 
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d. Pressure nozzle on pump hangs into sink 
10. Wash plate 5 times using the plate washer 
a. Fill each cell with buffer 
b. Shake with vigorousness adjuster set at a half or more for 30sec. 
c. Suck out buffer from each cell 
11. Tap several times hard onto paper towel to ensure any excess fluid removed. 
12. Remove one vial of serum for each patient from the -800c freezer to defrost 
Blocking buffer 
13. Add 127ul blocking buffer into each well – needs to be all the way to the top 
to block whole well otherwise HRP / luminol will stick to unblocked sites 
14. Cover the plate with plastic sticky foil, put the lid on 
15. Shake gently for 1hr at room temperature (vigorous setting at about a third)   
16. Wash 5 times using plate washer (with NaN3 and Tween) as above 
17. Make up a 2nd litre of wash buffer as above 
Serum 
18. Take the first vial of serum (trial number 1, first visit) 
19. Vortex the serum 
20. Pipette 30ul into each of the first 3 cells (A1-A3) 
21. Repeat for each patient vial, following the template already set up 
Standard 
22. Use 800pg/ml (even first row gets diluted) 
23. Use cells D22-P24 for standards  
24. Add 30ul control serum to all cells  
25. Add 30ul x 800pg/ml standard to cells P22-P24 
26. Pipette up and down several times to mix 
27. Take 30ul from each cell in row P 
28. Transfer to cells in row O 
29. Continue to double dilute across 3 cells up to row F 
30. Discard 30ul from final row (F) to leave 30ul 
31. Leave 3 cells in 2 rows (D&E) with control serum only to measure 
background 
32. Cover the plate with plastic sticky foil, put the lid on 
33. Shake gently for 10mins 
34. Incubate for 1hr at 37°c 
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35. Wash 5 times using wash buffer as above 
36. Make up a third litre of wash buffer as above but without NaN3 
Detection 
37. Use 50ng/ml detection 
38. Pipette 30ul x detection into each well 
39. Cover the plate with plastic sticky foil and put the lid on 
40. Shake gently for 10mins 
41. Incubate at 45min at 37°c 
42. Wash plate 5 times using wash buffer without NaN3  
HRP 
43. Switch on the Berthold Luminometer to preheat the lasers 
44. Dilute HRP (Sigma) (streptovirin in blue box in freezer) 1:10,000 with buffer 
45. i.e. 14ml buffer with 1.4ul HRP (tiny amount but can be done in one step)  
46. Use multichannel pipette to add 30ul HRP to each well 
47. Cover the plate with plastic sticky foil and put the lid on. 
48. Shake gently for 30mins at room temperature 
Luminol 
49. Prepare luminol : H2O2 dilution 1:1 in a tube covered with tin foil. Mix it 
gently and leave to incubate for 30mins at room temperature 
50. Wash plate five times using wash buffer without NaN3 
51. Add 30ul luminol mix to each well using the multi-channel pipette 
52. Cover the plate with silver foil and put in a draw 
53. Incubate for 10min at room temperature 
54. Put the plate in the luminometer (A1 at top right) 
55. Push down central plate, pull gripping frame down over the top 
56. Close machine 
57. On laptop chose simplistic 2.1 programme 
58. Chose correct plate size 
59. Can highlight only some cells and press the symbol with a spot inside a 
rectangle to read only those 
60. Press green spot symbol to read plate 
61. Transfers automatically to excel 
62. Save in my documents / susi & use memory stick to transfer to personal laptop 
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